



„Essen.Gesund.Vernetzt. - Medizinische Gesellschaft e.V.“
c/o EWG Essener Wirtschaftsförderungsgesellschaft e.V.
z. Hd. Claudia Anders
Kennedyplatz 5
45127 Essen

claudia.anders@ewg.de

Essen, den 21. Mai 2025

Jahrespreis 2025 „Gesundheit und Wissenschaft“
Anlagen

Sehr geehrte Frau Anders,
sehr geehrte Damen und Herren,

sehr gerne bewerbe ich mich mit der Arbeit „Neoadjuvant nivolumab with or without relatlimab in resectable non-small cell lung cancer: an open-label, randomized phase II trial“, die unsere Autorengruppe im Juni 2024 in der Zeitschrift *Nature Medicine* (Schuler et al., Nat. Med. 2024; 30:1602-1611) publizieren konnte, um den Jahrespreis 2025 in der Kategorie „Gesundheit und Wissenschaft“. Die Koautoren stimmen der Bewerbung zu.

Im Voraus danke ich für die Begutachtung der Arbeit durch die Jury des Jahrespreises.

Mit freundlichen Grüßen

Univ.-Prof. Dr. M. Schuler
Direktor der Inneren Klinik (Tumorforschung)
Geschäftsführender Direktor NCT West



Universitätsklinikum Essen
Hufelandstraße 55
45147 Essen

Tel. +49 (0) 201 – 723 – 0
Fax +49 (0) 201 – 723 – 4694
Web ume.de

Sitz der Institution: Essen
Institutskennzeichen: 260 510 381
USt.-ID: DE 119 656 585

Sparkasse Essen
IBAN DE82 3605 0105 0004 9007 00
BIC SPESDE33XXX

Grundinformationen

Univ.-Prof. Dr. med. Martin Schuler
Westdeutsches Tumorzentrum Essen
Innere Klinik (Tumorforschung)
Universitätsklinikum Essen
Hufelandstrasse 55
45147 Essen
Tel. (0201) 723 2000
Fax (0201) 723 5924
martin.schuler@ume.de

Persönliche Daten:

- geboren am 16. August 1966
- verheiratet mit Birgit Schuler, geb. Busse, Redakteurin
- Kinder Katharina und Antonia Schuler

Schul- und Hochschulbildung:

- 1972 bis 1976 Grundschule
- 1976 bis 1985 Gymnasium
- 1985 bis 1991 Studium der Medizin an der Johannes Gutenberg-Universität Mainz

Promotion:

- 20. Januar 1992, Johannes Gutenberg-Universität Mainz, Prädikat „magna cum laude“

Habilitation und venia legendi im Fach Innere Medizin:

- 14. Februar 2002, Johannes Gutenberg-Universität Mainz

Berufliche Qualifikationen:

- Facharzt für Innere Medizin
- Schwerpunktbezeichnungen Hämatologie und internistische Onkologie sowie Pneumologie
- Zusatzweiterbildung Palliativmedizin

Beruflicher Werdegang:

- 1991 bis 1997 Ausbildung zum Facharzt für Innere Medizin an der III. Medizinischen Klinik und Poliklinik (Direktor: Prof. Dr. Ch. Huber), mit Rotationen in die I. Medizinische Klinik und Poliklinik (Direktor: Prof. Dr. Dr. K.H. Meyer zum Büschenfelde) und II. Medizinische Klinik und Poliklinik (Direktor: Prof. Dr. J. Meyer), Klinikum der Johannes Gutenberg-Universität Mainz
- 1998 bis 2000 Postdoktorand (Mildred Scheel Stipendium), Division of Cellular Immunology (Leiter: Dr. D.R. Green), La Jolla Institute for Allergy & Immunology, San Diego, USA
- 2000 bis 2001 Research Scientist, Division of Cellular Immunology, La Jolla Institute for Allergy & Immunology, San Diego, USA
- 2001 bis 2007 Arbeitsgruppenleiter (Max-Eder-Nachwuchsgruppe der Deutschen Krebshilfe) an der III. Medizinischen Klinik und Poliklinik, Klinikum der Johannes Gutenberg-Universität Mainz
- 2002 bis 2007 Oberarzt und Leiter der Studienzentrale des Schwerpunktes Hämatologie und Onkologie, III. Medizinische Klinik und Poliklinik, Klinikum der Johannes Gutenberg-Universität Mainz
- seit 1. Oktober 2007 Universitätsprofessor (W3) für Innere Medizin der Universität Duisburg-Essen und Direktor der Inneren Klinik (Tumorforschung), Westdeutsches Tumorzentrum, Universitätsklinikum Essen
- seit 2009 gleichzeitig Chefarzt der Abteilung Thorakale Onkologie, Universitätsmedizin Essen - Ruhrlandklinik
- seit 2008 Stellvertretender Direktor, Westdeutsches Tumorzentrum Essen (Onkologisches Spitzenzentrum der Deutschen Krebshilfe)
- 2011 bis 2021 Sprecher des Partnerstandorts Essen-Düsseldorf, Deutsches Konsortium für Translationale Krebsforschung (DKTK)
- seit 2019 Sprecher des Campus Essen, Krebsforschungszentrum Essen Köln (Cancer Research Center Cologne Essen, CCCE)
- seit 2023 Sprecher des geschäftsführenden Direktoriums, Nationales Centrum für Tumorerkrankungen (NCT) West

Allgemeinverständlich formulierte Zusammenfassung der eingereichten Forschungsarbeit

Lungenkrebs ist die häufigste zum Tode führende bösartige Erkrankung in Deutschland wie auch global. Weiterhin wird die Mehrzahl der Betroffenen in einem metastasierten Stadium der Erkrankung diagnostiziert. Durch Früherkennungsmaßnahmen steigt erfreulicherweise der Anteil der Patienten mit bei Diagnose örtlich begrenzter Lungenkrebserkrankung, die häufig durch eine Operation mit dem Ziel der Heilung behandelt werden können. Leider erleiden trotz optimal durchgeführter Operation ein großer Teil dieser Patienten einen Rückfall. Dies ist durch eine zum Zeitpunkt der Diagnosestellung nicht erkennbare Streuung (Metastasierung) sowie durch aggressive biologische Eigenschaften bestimmter Lungenkarzinome erklärbar. Zur Senkung des Risikos eines Krankheitsrückfalls nach Operation wird Patienten mit größeren Tumoren oder Lymphknotenmetastasen nach der Operation eine „adjuvante“ Chemotherapie angeboten. Seit kurzem kann dies in bestimmten Fällen durch eine „adjuvante“ Immuntherapie ergänzt werden. Diese Maßnahmen sind wirksam, dennoch erleiden weiterhin zu viele Patienten einen Krankheitsrückfall. Neue Erkenntnisse sprechen dafür, dass die Immuntherapie eine größere Wirksamkeit hat, wenn diese vor der Operation („neoadjuvant“) verabreicht wird. Dies bietet darüber hinaus die Chance einer kürzeren Behandlungsdauer sowie die Möglichkeit, die weitere Behandlung anhand des Ansprechens auf die „neoadjuvante“ Therapie individuell anzupassen.

Die zur Begutachtung eingereichte Arbeit beschreibt die Ergebnisse einer klinischen Studie, die vom Antragsteller konzipiert und geleitet am Westdeutschen Tumorzentrum Essen sowie zwei weiteren, internationalen Lungenkrebszentren unter legaler Verantwortung (Sponsor nach Arzneimittelgesetz) der Universitätsmedizin Essen durchgeführt wurde. Insgesamt 60 Patienten mit chirurgisch behandelbaren nicht-kleinzelligen Lungenkarzinomen erhielten vor der Operation eine kurzzeitige Immuntherapie, die entweder aus zwei Gaben des zugelassenen Antikörpers Nivolumab oder zwei Gaben der Kombination von Nivolumab mit dem zum Zeitpunkt der Studie noch nicht zugelassenen Antikörper Relatlimab bestand. Diese Antikörper können durch Aktivierung einer körpereigenen Immunreaktion die Abtötung von Tumorzellen auslösen. Wichtige Ergebnisse der Studie sind (1) die kurzzeitige Immuntherapie kann sicher verabreicht werden ohne die Operation zu verzögern, und (2) bei bis zu 30% der Patienten waren zum Zeitpunkt der Operation bereits alle oder fast alle Tumorzellen durch die mit der Behandlung ausgelöste Immunantwort abgetötet. Darüber hinaus ermöglichen umfassende Untersuchungen der vor der Immunbehandlung und bei der Operation gewonnenen Tumorproben, Blutproben und Bilddaten wichtige Erkenntnisse zur Wirkweise der beiden, in der Krebstherapie eingesetzten Antikörper.

Zusammenfassende Kurzbeschreibung

Innovationspotential: Hoch

- Die weltweit erste veröffentlichte Studie zum Einsatz des gegen LAG-3 gerichteten Antikörpers Relatlimab in der Behandlung von Patienten mit Lungenkrebs
- Eine der weltweit ersten Studien der kombinierten Immuntherapie mit zwei Antikörpern vor Operation eines Lungenkarzinoms
- Erstmalige Beschreibung der Wirkung einer kurzzeitigen Immuntherapie mit Nivolumab und Relatlimab auf das Muster der Ausprägung von Genen („Genexpression“) sowie die Verteilung von Genmutationen („Mutationsspektrum“) von Lungenkarzinomen

Nachhaltigkeit: Hoch

- Die mit der eingereichten Arbeit gewonnenen Erkenntnisse fließen in die Weiterentwicklung der Immunbehandlung von Lungenkarzinomen in operablen und metastasierten Stadien mit Antikörpern gegen LAG-3 ein
- Die mit der eingereichten Arbeit gewonnenen Erkenntnisse zu den durch die Immuntherapie ausgelösten biologischen Veränderungen von Lungenkarzinomen informieren neue Strategien zur Entwicklung individuell abgestimmter Immunbehandlungen für Patienten mit Krebserkrankungen

Nachhaltige Verbesserung der Gesundheit und Lebensqualität: Erfüllt

- Der Nachweis der Wirksamkeit von Relatlimab in der Behandlung von Lungenkrebs erweitert die Behandlungsmöglichkeiten für Patienten mit dieser Erkrankung
- Ein verbessertes biologisches Verständnis der Wirkung von Immuntherapien bei Lungenkrebs ermöglicht die Entwicklung individuell abgestimmter, immunologischer Kombinationsbehandlungen mit höherer Wirkungsaussicht geringerem Risiko des Verabreichens von unwirksamen und nebenwirkungsreichen Therapien

Standortrelevanz für Essen: Hoch


- Die international beachtete Veröffentlichung der in Essen konzipierten, geleiteten und durchgeführten Arbeit in der Fachzeitschrift *Nature Medicine* (höchste Kategorie) erhöht die Sichtbarkeit und bestätigt die Bedeutung der Stadt Essen als international führendem Standort der Krebsforschung und Krebsmedizin
- Sie bestätigt die Auswahl des Westdeutschen Tumorzentrums der Universitätsmedizin Essen als Standort des Nationalen Centrum für Tumorerkrankungen (NCT) und festigt dessen durch regelmäßige internationale Begutachtungen bestätigte Anerkennung als Onkologisches Spitzenzentrum der Deutschen Krebshilfe

Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trial

Received: 29 November 2023

Accepted: 2 April 2024

Published online: 30 April 2024

 Check for updates

A list of authors and their affiliations appears at the end of the paper

Antibodies targeting the immune checkpoint molecules PD-1, PD-L1 and CTLA-4, administered alone or in combination with chemotherapy, are the standard of care in most patients with metastatic non-small-cell lung cancers. When given before curative surgery, tumor responses and improved event-free survival are achieved. New antibody combinations may be more efficacious and tolerable. In an ongoing, open-label phase 2 study, 60 biomarker-unselected, treatment-naïve patients with resectable non-small-cell lung cancer were randomized to receive two preoperative doses of nivolumab (anti-PD-1) with or without relatlimab (anti-LAG-3) antibody therapy. The primary study endpoint was the feasibility of surgery within 43 days, which was met by all patients. Curative resection was achieved in 95% of patients. Secondary endpoints included pathological and radiographic response rates, pathologically complete resection rates, disease-free and overall survival rates, and safety. Major pathological ($\leq 10\%$ viable tumor cells) and objective radiographic responses were achieved in 27% and 10% (nivolumab) and in 30% and 27% (nivolumab and relatlimab) of patients, respectively. In 100% (nivolumab) and 90% (nivolumab and relatlimab) of patients, tumors and lymph nodes were pathologically completely resected. With 12 months median duration of follow-up, disease-free survival and overall survival rates at 12 months were 89% and 93% (nivolumab), and 93% and 100% (nivolumab and relatlimab). Both treatments were safe with grade ≥ 3 treatment-emergent adverse events reported in 10% and 13% of patients per study arm. Exploratory analyses provided insights into biological processes triggered by preoperative immunotherapy. This study establishes the feasibility and safety of dual targeting of PD-1 and LAG-3 before lung cancer surgery. ClinicalTrials.gov Identifier: [NCT04205552](https://clinicaltrials.gov/ct2/show/study/NCT04205552).

Lung cancer is the leading cancer fatality on a global scale, with the number of deaths surpassing those of breast, colorectal and prostate cancer combined¹. Despite advances in early detection, the majority of patients are still diagnosed with advanced stage disease. The introduction of precision therapies targeting specific oncogenic mutations in lung adenocarcinomas (LUAD), and monoclonal antibodies modulating

the PD-1/PD-L1 and CTLA-4 immune checkpoints in non-small-cell lung cancers (NSCLC) and small-cell lung cancers have significantly improved treatment outcomes in metastatic disease^{2,3}. More recently, these paradigms have been successfully translated to treatment algorithms for localized NSCLC that are based on curative surgery. This includes adjuvant osimertinib following resection of *EGFR*-mutated

✉ e-mail: martin.schuler@uk-essen.de; kristof.cuppens@jessazh.be




Fig. 1 | Study design, patient disposition and secondary endpoints.

a, Graphical representation of clinical study design including key inclusion criteria. **b**, Patient disposition during the phases of the clinical study including screening, preoperative immunotherapy and curative resection. Reasons for screening failure and outcomes of surgery are summarized (*including one patient with single bone metastasis). **c**, Fraction of patients ($n = 60$) with microscopically complete (RO, green), microscopically incomplete (R1, purple) and macroscopically incomplete (pleural carcinosis, M1a (PLE), orange) resection

of primary lung cancers and, if present, lymph node metastases per study arm. **d**, Fraction of patients ($n = 60$) with complete (none), partial response (PR, green), stable (SD, yellow) and progressive disease (PD, red) per RECIST evaluation of CT scans per study arm. **e**, Fraction of patients ($n = 31$) with complete (none), partial metabolic response (PMR, green), metabolically stable (SMD, yellow) and metabolically progressive disease (PMD, red) per PERCIST evaluation of positron emission tomography scans per study arm. SoC, standard of care.

NSCLC⁴, alectinib in resected ALK-positive NSCLC⁵ and atezolizumab or pembrolizumab following resection and adjuvant chemotherapy in NSCLC^{6,7}.

Clinical and biological considerations provide strong arguments for moving relapse-preventing systemic therapies to the preoperative or perioperative setting. First, preoperative treatment is not delayed or prevented by postoperative morbidity and protracted recovery from surgery. Second, the response to risk-reducing cancer medicines can be monitored by imaging and histopathology of the primary tumor. Specifically in the setting of immune checkpoint inhibitor (ICI) therapy,

reinvigoration of a suppressed immune response may be more effective while tumor-infiltrating lymphocytes are still present in their native tumor context. Clinical proof-of-concept has been provided by the SWOG S1801 study in patients with resectable melanoma, which demonstrated improved disease-free survival (DFS) by moving 3 of 18 doses of pembrolizumab to the preoperative window⁸.

Several studies have piloted preoperative ICI therapy directed against PD-1, PD-L1, CTLA-4 and less-established targets in patients with resectable NSCLC^{9–13}. Next to demonstrating safety and feasibility, the spectra of clinical and histopathological responses observed

in these studies were correlated with exploratory biomarker analyses. More recently, preoperative PD-1/PD-L1 antibodies combined with platinum-based chemotherapy have been explored^{14–18}. Although this approach resulted in impressive histopathological response rates and improved event-free survival, combined chemoimmunotherapy may obscure the contribution of the ICI component at the single patient level. Across larger studies of preoperative chemoimmunotherapy approximately 20% of patients failed to proceed to curatively intended surgery. Further, patients who might have been served perfectly well with ICI therapy alone were exposed to the additional toxicities of chemotherapy.

Studies combining two ICIs in unselected patient populations with metastatic NSCLC have so far produced similar outcomes to therapies targeting PD-1/PD-L1 alone or combined with chemotherapy^{19–22}. Nevertheless, it is conceivable that simultaneous blockade of more than one immune checkpoint can extend clinical activity to yet undefined patient populations or prolong duration of disease control.

Based on their distinct and potentially synergistic mode of action, combined targeting of the immune checkpoints LAG-3 and PD-1 is a rational choice to overcome immune resistance in NSCLC. Both PD-1 and LAG-3 are expressed by exhausted T cells. Dual blockade of both immune checkpoints synergistically enhanced T cell function and anti-tumor activity in preclinical models^{23,24}. Importantly, in a randomized phase 3 study in patients with unresectable or metastatic melanoma combining the PD-1 antibody nivolumab and relatlimab, an immunoglobulin G4 antibody blocking LAG-3 was superior to nivolumab monotherapy in terms of radiographic response and progression-free survival endpoints²⁵. Combination therapy was safe despite some increase in treatment-related adverse events (AEs), particularly thyroiditis, diarrhea and hepatitis. Myocarditis was reported in 1.7% of patients receiving nivolumab and relatlimab under routine troponin monitoring²⁵. This study supported approvals of this novel ICI combination therapy by the U.S. Food and Drug Administration and the European Medicines Agency.

Against this background, the study NEOpredict-Lung (NCT04205552) was designed to explore the feasibility and safety of preoperative dual targeting of PD-1 and LAG-3 in patients with resectable NSCLC stages IB, II or IIIA (Fig. 1a and Supplementary information). Secondary endpoints include the assessment of pathological and radiographic responses, survival endpoints and quality of surgical resections. Moreover, the study intends to leverage the neoadjuvant setting for exploratory analyses of specific biologies associated with response or resistance. Patients are randomly assigned to nivolumab plus relatlimab or nivolumab monotherapy, the latter serving as a reference for the evaluation of toxicity, clinical activity and biological impact of dual targeting of PD-1 and LAG-3 in resectable NSCLC.

Results

Study design and patient disposition

Between 4 March 2020 and 25 July 2022, 64 patients were screened and 60 patients were enrolled at three study sites. All patients provided written informed consent; study participation was not compensated. Patients were randomized between two preoperative treatments given every 14 days with nivolumab (240 mg, arm A) and nivolumab plus relatlimab (240 mg and 80 mg, arm B) (Fig. 1a,b). Demographics and patient characteristics are summarized in Table 1. Fifty-eight (97%) patients received the planned two doses of nivolumab or nivolumab plus relatlimab; the second dose of nivolumab or nivolumab plus relatlimab was withheld in one patient each because of immune-related AEs, which fully resolved subsequently. All 60 patients (100%) proceeded to surgery within the protocol-defined time frame. Clinical data are reported as of 16 May 2023.

Primary outcome

The clinical study was designed to confirm the feasibility of two preoperative doses of nivolumab plus relatlimab or nivolumab without delaying curatively intended surgery (Fig. 1a). Based on analyses of surgical

Table 1 | Patient demographics and characteristics

	Nivolumab	Nivolumab plus relatlimab
n (female, male)	30 (15, 15)	30 (13, 17)
Age in years, median (range)	64 (43–77)	67 (43–81)
ECOG PS (0, 1)	28, 2	28, 2
Histology		
Adenocarcinoma	13	15
Squamous cell carcinoma	10	9
Adenosquamous carcinoma	2	2
Other	5	4
Clinical stage (UICC eighth edition)		
IB	8	10
IIA	5	1
IIB	13	16
IIIA	4	3
PD-L1 status (TPS)		
<1%	6	8
1–49%	14	15
≥50%	10	7
Smoking status		
Current	5	16
Former	22	13
Nonsmoker	3	1
Occupational exposure		
Yes	2	3
No	27	26
Unknown	1	1

ECOG PS, Eastern Cooperative Oncology Group performance score; TPS, tumor proportional score.

registries²⁶ a screening period of up to 28 days and a treatment period of up to 42 days were considered safe with respect to surgical survival outcomes. The primary study endpoint was met by all 60 randomized patients, thus confirming feasibility of both arms of preoperative ICI treatment.

Secondary outcomes

Radiographic responses to immunotherapy were evaluated immediately before surgery per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1. There were no complete radiographic responses; the partial response rates were 10% with nivolumab monotherapy and 27% with nivolumab plus relatlimab (Fig. 1d).

Pathological response was evaluated in resected tumors and lymph nodes from 59 patients (30 in arm A and 29 in arm B) at each study site following standardized criteria²⁷. There were four (13%) complete pathological responses with nivolumab and five (17%) complete pathological responses with nivolumab plus relatlimab (Fig. 2d). The rates of major pathological responses (MPR, ≤10% viable tumor cells) were 27% and 30% (Fig. 2d), pathological responses (≤50% viable tumor cells) were observed in 60% and 72% of resected tumors and lymph nodes, respectively. In both study arms, deeper pathological responses clustered in patients with PD-L1-positive tumors (Fig. 2a).

Complete surgical resection (R0) was achieved in 57 patients (95%) (Fig. 1c). One patient had R1 resection; pleural carcinosis was detected intraoperatively in two patients, which had been undetectable by preoperative imaging studies. In one patient, a single small bone metastasis was detected during perioperative hospitalization. The treatment




Fig. 2 | Pathological responses, biomarkers and survival outcomes. **a**, Waterfall plots of pathologic tumor regression (percentage reduction of viable tumor cells) in resected tumors and lymph nodes following neoadjuvant treatment with nivolumab (arm A, blue) or nivolumab and relatlimab (arm B, red). The color intensity encodes the category of PD-L1 expression by tumor cells (TPS <1% light color, TPS 1–49% medium dark color, TPS 50–100% dark color). The lower panel depicts the oncogram of each tumor using next-generation DNA sequencing of 500 cancer-related genes. Boxes represent pathogenic genomic aberrations in the respective gene. Genes with pathogenic aberrations in at least two study patients are listed. **b**, Kaplan–Meier plots for OS (left) and DFS (right)

per study arm (arm A nivolumab, blue; arm B nivolumab and relatlimab, red). **c**, Kaplan–Meier plot for DFS in patients achieving a MPR (≤10% viable tumor cells (green)), and not achieving a MPR (>10% viable tumor cells (orange)). Statistical comparisons by log-rank test, vertical lines indicate censored patients. Two patients (both arm A) had died from noncancer causes. Six patients (four in arm A and two in arm B) have recurred or died. No patient with MPR has recurred, one patient with MPR had died from a noncancer cause. **d**, Fraction and number of patients with complete pathological response (pCR, upper) and MPR (lower) in study arms A (nivolumab (blue)) and B (nivolumab and relatlimab (red)).

plan remained curative for oligometastatic disease: primary tumor and lymph nodes were R0 resected, followed by postoperative standard of care systemic therapy and stereotactic radiotherapy (Fig. 1b). Including this patient, 30 patients have received standard of care postoperative chemotherapy (15 per arm), whereas 30 patients underwent no further adjuvant treatment.

With a median duration of follow-up of 12 months, rates of DFS and overall survival (OS) at 12 months were 89% and 93% with nivolumab monotherapy, and 93% and 100% with nivolumab plus relatlimab (Fig. 2b). So far, no patient achieving MPR has relapsed; one patient with MPR died from pulmonary embolism during extended follow-up (Fig. 2c).

Safety

Of 60 randomized and treated patients, 92% experienced at least one AE during preoperative immunotherapy. The most common AEs included mild to moderate respiratory symptoms, thyroid function abnormalities, gastrointestinal symptoms, fatigue, laboratory abnormalities and musculoskeletal symptoms (Table 2). Serious AEs were observed in 30% (arm A) and 33% (arm B) of patients, respectively. Treatment-emergent AEs were reported in 53% (arm A) and 63% (arm B) of patients (Table 2). The most common immune-related AEs were hyperthyroidism and hypothyroidism. Grade 3 hyperthyroidism was observed in one patient (arm A). Additional immune-related AEs included increased liver enzymes and arthralgia (Table 2). In arm A there were two cases of pneumonitis (grade 1 and 2); likewise there were two cases in arm B (both grade 1).

No patient died during preoperative immunotherapy, the postoperative 90-day mortality was 3%. Two patients (both arm A) died during extended follow-up. One patient succumbed to acute pulmonary embolism 62 days after the first dose of nivolumab. Another patient developed cryptogenic liver failure 103 days after start of study treatment with fatal outcome. A relation to nivolumab could not be excluded (Fig. 2b).

Exploratory outcomes

Metabolic responses. In 31 patients enrolled at site Essen radiographic and metabolic responses to study therapy were evaluated by positron emission tomography/computed tomography using the tracer [¹⁸F]-fluorodeoxyglucose (FDG-PET/CT) (Supplementary Fig. 1). The metabolic response rates per Positron Emission tomography Response Criteria In Solid Tumors (PERCIST)²⁸ were 38% in both study arms (Fig. 1e). All patients with MPR had a partial metabolic response, and 8 of 12 patients (67%) with partial metabolic response had achieved MPR (Extended Data Fig. 1). By comparison of preoperative clinical and postoperative pathological tumor stage, nodal upstaging was observed in 4 of 5 patients (3 of 4 in arm A and 1 of 1 in arm B) with metabolic progression, but only in 2 of 25 patients (1 per arm) with metabolically stable disease or partial metabolic response (Extended Data Fig. 1).

Immune cell phenotyping. Immune cell subsets were studied by multiparametric flow cytometry in the peripheral blood (*n* = 38) (Supplementary Fig. 2a) and in resected primary tumors (*n* = 40) (Supplementary Fig. 2b,c) whenever feasible. At baseline there was no apparent difference in CD8⁺ and CD8⁺Granzyme B⁺ (GrzB⁺) peripheral blood T cells between patients with pathological response (≤50% viable tumor cells) and nonresponders. After 4 weeks of immunotherapy responders exhibited a significant increase in CD8⁺ and CD8⁺GrzB⁺ peripheral blood T cells compared with nonresponders (Fig. 3a). Comparable effects were observed in responders treated with nivolumab monotherapy (*n* = 13, *P* = 0.04) and nivolumab plus relatlimab (*n* = 13, *P* = 0.068) (Extended Data Fig. 2a). Importantly, immune cell infiltrates of resected tumors from patients with MPR contained fewer CD16⁺ neutrophil granulocytes, CD14⁺ monocytes and CD4⁺CD25⁺ regulatory T cells compared with resected lung cancers without MPR (Fig. 3b and Extended Data Fig. 2b).


Table 2 | Summary of adverse events

	Nivolumab <i>n</i> (%)	Nivolumab plus relatlimab <i>n</i> (%)
AE	27 (90)	28 (93)
Grade ≥ 3	12 (40)	16 (53)
Serious	9 (30)	10 (33)
Led to death	2 (7)	—
Prolonged hospitalization	8 (27)	10 (33)
Important medical event	1 (3)	1 (3)
Treatment-emergent AE	16 (53)	19 (63)
Grade ≥ 3	3 (10)	4 (13)
Led to death	1 (3)	—
Treatment-emergent AE with incidence ≥10% at least in one arm		
Atrial fibrillation	5 (17)	2 (7)
Hyperthyroidism	7 (23)	7 (23)
Hypothyroidism	3 (10)	5 (17)
Diarrhea	3 (10)	3 (10)
Nausea	1 (3)	3 (10)
Fatigue	8 (27)	4 (13)
Dyspnea	4 (13)	2 (7)
Pleural effusion	1 (3)	3 (10)
Pruritus	3 (10)	4 (13)
Noncardiac chest pain	1 (3)	3 (10)
Embolism	3 (10)	1 (3)
Hypertension	4 (13)	—
ALT increase	2 (7)	4 (13)
AST increase	2 (7)	4 (13)
Arthralgia	1 (3)	4 (13)
Immune-related AE with incidence ≥10% at least in one arm		
Hyperthyroidism	7 (23)	7 (23)
Hypothyroidism	3 (10)	5 (17)
Arthralgia	1 (3)	4 (13)
ALT increase	2 (7)	4 (13)
AST increase	2 (7)	4 (13)

ALT, alanine aminotransferase; AST, aspartate aminotransferase.

Expression of immune- and cancer pathway-related genes.

To dissect the impact of nivolumab with or without relatlimab on immune-related and cancer pathway-related gene sets, we compared the expression profiles of 15 pretreatment tumor biopsies (6 in arm A and 9 in arm B) and 43 resected lung tumors (21 in arm A and 22 in arm B). In both study arms, *CXCL2* and *CXCR4*, encoding an inflammation-associated chemokine and receptor, were strongly induced. In addition, nivolumab modulated a diverse spectrum of genes involved in inflammation, NFκB signaling and interferon response such as *NFKB1*, *TNFAIP3*, *CD8A*, *IRAK1* and *MX1*. Expression of the immune checkpoint gene *LAG3* was significantly induced by nivolumab, but not by the nivolumab/relatlimab combination (Fig. 3c). Studying resected tumors from nivolumab-treated patients in relation to MPR, a heterogeneous pattern without statistically significant changes in gene expression levels emerged. By contrast, MPR following nivolumab plus relatlimab was significantly associated with suppressed gene programs linked to granulocytes, monocytes and macrophages such as *CD24*, *CXCL1*, *CXCL14*, *IL8*, *MIF* and *ISG15*. Significantly upregulated genes in responders to nivolumab plus relatlimab included *NLRP3*, *CD27*, *IRF4* and *IL16*, which are involved in inflammasome and NFκB signaling,



the interferon response and T cell activation. In addition, a cluster of genes associated with epithelial and cancer cells (for example, *CDH1*, *EPCAM*, *BIRC5* and *CD276*) was significantly downregulated in resected tumors with nivolumab/relatlimab-induced MPR (Fig. 3d).

Shaping of cancer genomes by immunotherapy. In 43 patients, pretreatment tumor biopsies, resected tumors and normal tissue of sufficient quality and quantity were obtained to longitudinally explore the mutational profiles of a comprehensive set of cancer-related genes.

Fig. 3 | Immune cell subsets and gene expression in peripheral blood and resected tumors. **a**, Fraction of total CD8⁺ T cells (left), CD8⁺GrzB⁺ effector T cells (center) and CD8⁺GrzB[−] T cells (right) in the peripheral blood of responding ($\leq 50\%$ viable tumor cells in resected tumors and lymph nodes) and nonresponding patients ($> 50\%$ viable tumor cells). Each dot represents an individual patient: baseline values are in black and values at day 28 are in red. Whiskers and boxes represent the minimum, first, second and third quartiles and the maximum. Wilcoxon matched pairs signed-rank test was applied for statistical comparison. All *P* values are two-sided, no adjustments were made for multiple comparisons. **b**, Fraction of CD16⁺ neutrophil granulocytes (left), CD14⁺ monocytes (center) and CD4⁺CD25⁺ regulatory T cells (T_{reg}, right) in single-cell suspensions from resected tumors. Each dot or box represents a single patient (black, nivolumab; red, nivolumab and relatlimab; MPR, $\leq 10\%$ viable tumor cells in resected tumors and lymph nodes; no MPR, $> 10\%$ viable tumor cells). Horizontal lines indicate the mean and s.e.m. **c**, Differential expression

of immune-related and cancer pathway-related genes in response to treatment with nivolumab (left) and nivolumab and relatlimab (right) are presented as volcano plots. Significantly ($FDR \leq 0.05$) upregulated (right of 0 line on *x* axes) and downregulated (left of 0 line on *x* axes) genes are depicted as blue closed circles. Selected significantly regulated genes are indicated. *P* values on the *y* axes were calculated using the two-sided quasi-likelihood F-test approach of EdgeR. **d**, Differential expression of immune-related genes and cancer pathway-related genes in resected tumors with MPR following treatment with nivolumab (left) and nivolumab and relatlimab (right) compared with resected tumors without MPR. Significantly ($FDR \leq 0.05$) upregulated (right of 0 line on *x* axes) and downregulated (left of 0 line on *x* axes) genes in tumors with MPR are depicted as blue closed circles. Selected significantly regulated genes are indicated. *P* values on the *y* axes were calculated using the two-sided quasi-likelihood F-test approach of EdgeR. There was no significant interaction with MPR following nivolumab treatment.

Tumor biopsies taken at diagnosis revealed no apparent clustering of recurring mutations in patients with or without a histopathological response (Fig. 2a). There were three patients with *EGFR*-mutated tumors (arm A: *EGFR* insertion exon 20; arm B: *EGFR* deletion exon 19 and co-mutation of *EGFR* p.G719A and p.S768L), who had 95% (arm A) and 50% viable tumor cells (both in arm B) following study therapy. No *ALK* or *ROS1* gene fusions or other oncogenic drivers susceptible to approved targeted first-line therapies of NSCLC were identified.

Longitudinal analyses of the global mutational spectra comparing diagnostic biopsies and resected tumors at the single patient level were performed using whole-exome sequencing. These spectra appeared to be not significantly altered in resected tumors of patients who failed to substantially respond to preoperative ICI therapy, whereas reduced mutational diversity was observed in tumors with deeper pathological responses (Fig. 4a). Pretreatment and posttreatment samples from 14 patients met stringent prerequisites for inferring the dynamics of subclonal diversity (see Methods for details). This revealed strong evidence of genomic remodeling in immunotherapy responders. Mutational spectra of resected tumors from patients with deeper pathological response to immune checkpoint blockade exhibited both enrichment and depletion of subclones, whereas some tumors were skewed toward reduced diversity (Fig. 4b). In selected cases enrichment of cancer gene mutations, such as copy number gain of *MYC* and *KRAS*, and pathogenic variants of *IDH1* and *STK11*, was observed in residual tumor cells following study therapy (Fig. 4c and Supplementary Fig. 3).

Discussion

Immunotherapy with antibodies blocking the immune checkpoint molecules PD-1, PD-L1 and CTLA-4 has become standard of care for patients with metastatic NSCLC not harboring oncogenic mutations of *EGFR*, *ALK*, *ROS1* or *RET*^{21,22,29–34}. Consequently, their potential to reduce the risk of disease recurrence and death following curatively intended

therapies such as chemoradiotherapy³⁵ and surgery is explored in locally advanced or localized NSCLC. Preoperative ICI therapy is a particularly attractive strategy. Short-course treatment with antibodies blocking PD-1 or PD-L1 alone or combined with platinum-based chemotherapy may induce deep pathological responses, which are associated with favorable survival outcomes^{36,37}. Although there is a clear interaction between ICI and chemotherapy in terms of efficacy, the added toxicities of chemotherapy are not required in all NSCLC patients to unfold the full curative potential of ICI treatment.

Against this background, combined targeting of further immune checkpoints in addition to the PD-1/PD-L1 axis is a rational next step in the development of preoperative immunotherapy of NSCLC. The phase 2 study NEOSTAR¹⁰ randomized 21 patients to three preoperative doses of nivolumab (anti-PD-1) and a single dose of ipilimumab (anti-CTLA-4). Of 16 patients (76%) subsequently undergoing resection, 6 achieved complete pathological responses (29%), and grade ≥ 3 toxicities were reported in 10%. This was further explored in the phase 3 study CheckMate 816, which in its third arm randomized 113 patients with resectable NSCLC to preoperative nivolumab and ipilimumab¹³. Of those, 74% proceeded to definitive surgery, which revealed complete pathological responses in 23 patients (20%). Grade ≥ 3 toxicities were observed in 20% of patients. Although the early efficacy outcomes of both studies are promising, the toxicities and relatively low fraction of operated patients leave room for improvement.

The current study, NEOpredict-Lung, aims to establish the feasibility of combining the PD-1 blocking antibody, nivolumab, and the LAG-3 blocking antibody, relatlimab, in preoperative treatment of NSCLC patients. When the study was conceived and initiated this ICI combination was still in clinical development. Therefore, patients were randomized to nivolumab with or without relatlimab, with monotherapy serving as a reference for safety, feasibility, efficacy and exploratory endpoints. The study was not designed for formal


Fig. 4 | Dynamic changes in the mutational spectra in response to immunotherapy. **a**, Prevalence of mutations per megabase (Mb, *y* axes) of 500 cancer-related genes in pretherapeutic diagnostic biopsies (left) and resected tumors (right) of two exemplary patients without (001-R-010) and with response (002-R-052) to study therapy. The specific mutations (nucleotide exchanges from C to A (C>A), G (C>G) or T (C>T), from T to A (T>A), C (T>C) or G (T>G), complex nucleotide replacements (complex) or multiple nucleotide variants (MNV)) are color-coded from dark blue to yellow. The minimal VAFs are depicted on the *x* axes. **b**, Subclonal dynamics between pretherapeutic biopsies and resected tumors of 14 patients; each line depicts an individual patient. Left, pathological regression (percentage reduction of viable tumor cells) following immunotherapy. Center, estimated total number of subclones in the resected tumor. Right, fraction of subclones enriched ('fraction gained') and depleted ('fraction lost') in the resected tumors. Fractions are visualized by color (with yellow for high, purple for low), and bubble size (large for high, small for low, no bubble for zero). **c**, Selection of genomically encoded putative resistance

mechanisms in one of 43 patients with pretreatment and posttreatment tumor specimens for genomic analyses. Left, representative microphotographs of the pretherapeutic diagnostic tumor biopsy stained with H&E and with an anti-PD-L1 primary antibody. DNA sequencing of the tumor biopsy revealed pathogenic mutations of *KRAS* and *TP53* and amplification of the CD274 (PD-L1)-encoding gene. Center, low magnification image of a H&E-stained section of the resected tumor showing massive necrosis, but a residual region of vital tumor cells on the left-hand margin. Right, high magnification photomicrographs representing the transition zone from necrotic tumor to residual viable tumor cells stained with H&E and with an anti-CD8 primary antibody demonstrating tumor-infiltrating T lymphocytes. DNA sequencing of the resected tumor confirmed the presence of pathogenic mutations of *KRAS* and *TP53* and amplification of the CD274 (PD-L1)-encoding gene. In addition, copy number gain of *MYC* and a pathogenic *IDH1* mutation were newly detected. A complete list of patients with enrichment of genomically encoded putative resistance mechanisms in resected tumors is presented in Supplementary Fig. 3.

statistical comparison of both treatment arms. In the meantime, nivolumab plus relatlimab combination therapy has been globally approved for the treatment of patients with unresectable or metastatic cutaneous melanoma, thus supporting the rationale and providing an extensive safety database²⁵. With all randomized patients reaching the primary study endpoint, that is proceeding to surgery within 43 days of initiation of ICI therapy, NEOpredict-Lung confirms the feasibility of both study arms. Achieving R0 resections in 95% of patients compares favorably with other studies of ICI-based neoadjuvant treatment in NSCLC with operation rates mostly around 80%^{9,11–18}. The safety of preoperative nivolumab plus relatlimab was supported with no apparent difference in overall frequency and severity of AEs,

treatment-related AEs and immune-related AEs compared with the reference nivolumab (Table 2).

With respect to secondary efficacy endpoints, the study NEOpredict-Lung has several limitations. First, the moderate sample size and study design preclude formal assessment of clinical efficacy, and appreciation of an additional contribution of relatlimab to pathological and radiographic response rates and survival endpoints. It seems apparent that deeper histopathological responses to nivolumab with or without relatlimab cluster in patients with PD-L1-positive NSCLC (Fig. 2a). Because randomization was not stratified for PD-L1 status, the imbalanced distribution of patients with PD-L1 highly positive NSCLC between study arms (Table 1) may have skewed deep pathological



response rates in favor of nivolumab monotherapy. The exclusion of patients with extensive mediastinal lymph node metastases may have contributed to the excellent surgical results and early survival outcomes in NEOpredict-Lung compared with other studies of pre-operative ICI combinations.

Obtaining comprehensive cellular and molecular portraits of lung cancers within their tissue context is key to advancing the mechanistic understanding of response and resistance to ICI therapy. Against this background, administering ICI before lung cancer surgery is an important step allowing exploratory analyses of treatment-induced biological processes. The study NEOpredict-Lung provides insights into potential mechanisms of resistance to ICI therapy in NSCLC. The patient cohort covered the entire spectrum of histopathological responses in both treatment arms (Fig. 2a). This enabled exploratory correlation of translational endpoints with patient outcomes. Immune cell phenotyping demonstrated an increase in CD8⁺GrzB⁺ effector T cells in the peripheral blood of responding patients (Fig. 3a), which is in line with findings from other studies. Likewise, correlative studies in NEOSTAR demonstrated greater infiltration of CD3⁺CD8⁺GrzB⁺ T lymphocytes upon combined blockade of PD-1 and CTLA-4 (ref. 10). Although these patterns are consistent across both trials, methods and endpoints of correlative analyses were not aligned precluding direct comparison.

The negative correlation of histopathological response with the intratumoral representation of suppressive immune cell subsets is a key finding of our study. This is orthogonally supported at the cellular level by the enrichment of granulocytes, monocytes and regulatory T cells in resected tumors not achieving a MPR (Fig. 3b), and at the molecular level by gene expression analyses. In tumors with MPR following nivolumab plus relatlimab there was a significant suppression of gene programs linked to granulocytes, monocytes and macrophages (Fig. 3d). These findings provide important leads for further mechanistic studies and toward the nomination of biologically rational therapeutic targets for combination therapies. Assessing dynamic changes in the expression of immune-related genes between pretreatment biopsies and resected tumors, an interesting pattern emerged. Reassuringly, *CXCL2* and *CXCR4* encoding inflammation-associated chemokine proteins were most significantly induced by nivolumab with or without relatlimab (Fig. 3c). In addition, nivolumab associated with a very diverse spectrum of genes that were significantly upregulated or downregulated. By contrast, the change in gene expression patterns following nivolumab plus relatlimab therapy was more homogenous. This is also reflected by the absence of a significant correlation of gene expression changes in nivolumab responders (Fig. 3d). These findings argue for a more consistent and directed immune activation by combined treatment with nivolumab plus relatlimab, which may provide opportunities for rational triplet combinations that may have the capacity to expand the responding patient population.

Another key observation of NEOpredict-Lung is how rapidly ICI-induced immune activation may shape the individual genomic landscapes of NSCLC (Fig. 4). Our findings suggest that in a subgroup of patients nivolumab with or without relatlimab failed to reinvigorate an immune response that significantly impacts on clonally diverse tumors. In another subgroup four weeks of nivolumab with or without relatlimab were sufficient to empower complete immune eradication of lung cancers, which precluded meaningful longitudinal genomic analyses. Interestingly, in a third subgroup of patients who achieved substantial but not complete histopathological responses the enrichment of apparently resistant clones and depletion of sensitive clones was observed under the selective pressure mounted during preoperative ICI therapy. The latter hypothesis is corroborated by selected cases in which emergence of biologically plausible genomic resistance mechanisms, such as copy number gain of *MYC* and *KRAS*, and pathogenic variants of *IDH1* and *STK11*, is observed by longitudinal genome sequencing (Fig. 4c and Supplementary Fig. 3).

In conclusion, the study NEOpredict-Lung establishes the feasibility and safety of preoperative treatment with nivolumab and relatlimab in patients with resectable NSCLC stages IB, II and IIIA. Based on early signals of clinical and biological activity obtained with this and another recently reported study in patients with metastatic NSCLC³⁸ further exploration of dual targeting of PD-1 and LAG-3 in NSCLC is clearly warranted.

Online content

Any methods, additional references, Nature Portfolio reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at <https://doi.org/10.1038/s41591-024-02965-0>.

References

- Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J. Clin.* **71**, 209–249 (2021).
- Reck, M., Remon, J. & Hellmann, M. D. First-line immunotherapy for non-small-cell lung cancer. *J. Clin. Oncol.* **40**, 586–597 (2022).
- Tan, A. C. & Tan, D. S. W. Targeted therapies for lung cancer patients with oncogenic driver molecular alterations. *J. Clin. Oncol.* **40**, 611–625 (2022).
- Tsuboi, M. et al. Overall survival with osimertinib in resected EGFR-mutated NSCLC. *N. Engl. J. Med.* **389**, 137–147 (2023).
- Solomon, B. J. et al. LBA2 ALINA: efficacy and safety of adjuvant alectinib versus chemotherapy in patients with early-stage ALK+ non-small cell lung cancer (NSCLC). *Ann. Oncol.* **34**, S1295–S1296 (2023).
- Felip, E. et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. *Lancet* **398**, 1344–1357 (2021).
- O'Brien, M. et al. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial. *Lancet Oncol.* **23**, 1274–1286 (2022).
- Patel, S. P. et al. Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma. *N. Engl. J. Med.* **388**, 813–823 (2023).
- Forde, P. M. et al. Neoadjuvant PD-1 blockade in resectable lung cancer. *N. Engl. J. Med.* **378**, 1976–1986 (2018).
- Cascone, T. et al. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. *Nat. Med.* **27**, 504–514 (2021).
- Chaft, J. E. et al. Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial. *Nat. Med.* **28**, 2155–2161 (2022).
- Cascone, T. et al. Neoadjuvant durvalumab alone or combined with novel immuno-oncology agents in resectable lung cancer: the phase II NeoCOAST platform trial. *Cancer Discov.* **13**, 2394–2411 (2023).
- Awad, M. M. et al. 1261O Neoadjuvant nivolumab (N) + ipilimumab (I) vs chemotherapy (C) in the phase III CheckMate 816 trial. *Ann. Oncol.* **34**, S731 (2023).
- Cascone, T. et al. Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial. *Nat. Med.* **29**, 593–604 (2023).
- Forde, P. M. et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. *N. Engl. J. Med.* **386**, 1973–1985 (2022).
- Provencio, M. et al. Perioperative nivolumab and chemotherapy in stage III non-small-cell lung cancer. *N. Engl. J. Med.* **389**, 504–513 (2023).

17. Wakelee, H. et al. Perioperative pembrolizumab for early-stage non-small-cell lung cancer. *N. Engl. J. Med.* **389**, 491–503 (2023).
18. Heymach, J. V. et al. Perioperative durvalumab for resectable non-small-cell lung cancer. *N. Engl. J. Med.* **389**, 1672–1684 (2023).
19. Boyer, M. et al. Pembrolizumab plus ipilimumab or placebo for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score $\geq 50\%$: randomized, double-blind phase III KEYNOTE-598 study. *J. Clin. Oncol.* **39**, 2327–2338 (2021).
20. Hellmann, M. D. et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. *N. Engl. J. Med.* **381**, 2020–2031 (2019).
21. Paz-Ares, L. et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. *Lancet Oncol.* **22**, 198–211 (2021).
22. Johnson, M. L. et al. Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non-small-cell lung cancer: the phase III POSEIDON study. *J. Clin. Oncol.* **41**, 1213–1227 (2023).
23. Huang, C. T. et al. Role of LAG-3 in regulatory T cells. *Immunity* **21**, 503–513 (2004).
24. Aggarwal, V., Workman, C. J. & Vignali, D. A. A. LAG-3 as the third checkpoint inhibitor. *Nat. Immunol.* **24**, 1415–1422 (2023).
25. Tawbi, H. A. et al. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. *N. Engl. J. Med.* **386**, 24–34 (2022).
26. Yang, C. J. et al. Impact of timing of lobectomy on survival for clinical stage IA lung squamous cell carcinoma. *Chest* **152**, 1239–1250 (2017).
27. Travis, W. D. et al. IASLC multidisciplinary recommendations for pathologic assessment of lung cancer resection specimens after neoadjuvant therapy. *J. Thorac. Oncol.* **15**, 709–740 (2020).
28. Wahl, R. L., Jacene, H., Kasamon, Y. & Lodge, M. A. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. *J. Nucl. Med.* **50**, 122S–150S (2009).
29. Reck, M. et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. *N. Engl. J. Med.* **375**, 1823–1833 (2016).
30. Herbst, R. S. et al. Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC. *N. Engl. J. Med.* **383**, 1328–1339 (2020).
31. Sezer, A. et al. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. *Lancet* **397**, 592–604 (2021).
32. Gandhi, L. et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. *N. Engl. J. Med.* **378**, 2078–2092 (2018).
33. Paz-Ares, L. et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. *N. Engl. J. Med.* **379**, 2040–2051 (2018).
34. Socinski, M. A. et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. *N. Engl. J. Med.* **378**, 2288–2301 (2018).
35. Spigel, D. R. et al. Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. *J. Clin. Oncol.* **40**, 1301–1311 (2022).
36. Rosner, S. et al. Five-year clinical outcomes after neoadjuvant nivolumab in resectable non-small cell lung cancer. *Clin. Cancer Res.* **29**, 705–710 (2023).
37. Deutsch, J. S. et al. Association between pathologic response and survival after neoadjuvant therapy in lung cancer. *Nat. Med.* **30**, 218–228 (2024).
38. Gutierrez, M. et al. Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim results. *Nat. Med.* **29**, 1718–1727 (2023).

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2024

Martin Schuler^{1,2,3}✉, **Kristof Cuppens**^{4,5}✉, **Till Plönes**^{2,6,18}, **Marcel Wiesweg**^{1,2,3}, **Bert Du Pont**⁷, **Balazs Hegedus**^{2,6}, **Johannes Köster**^{1,2,3,8}, **Fabian Mairinger**^{2,9}, **Kaid Darwiche**^{1,2,3,10}, **Annette Paschen**^{1,2,11}, **Brigitte Maes**¹², **Michel Vanboeckrijck**¹³, **David Lähnemann**^{1,2,8}, **Fang Zhao**^{1,2,11}, **Hubertus Hautzel**^{1,2,3,14}, **Dirk Theegarten**^{2,9}, **Koen Hartemink**¹⁵, **Henning Reis**^{2,9,16}, **Paul Baas**¹⁷, **Alexander Schramm**^{1,2,20} & **Clemens Aigner**^{1,2,6,19,20}

¹West German Cancer Center, Department of Medical Oncology, University Hospital Essen, Essen, Germany. ²Medical Faculty, University Duisburg-Essen, Essen, Germany. ³National Center for Tumor Diseases (NCT) West, Essen, Germany. ⁴Department of Pulmonology and Thoracic Oncology, and Jessa and Science, Jessa Hospital, Hasselt, Belgium. ⁵Faculty of Medicine and Life Sciences LCRC, UHasselt, Diepenbeek, Belgium. ⁶West German Cancer Center, Department of Thoracic Surgery, University Medicine Essen – Ruhrlandklinik, Essen, Germany. ⁷Department of Thoracic and Vascular Surgery, Jessa Hospital, Hasselt, Belgium. ⁸Bioinformatics and Computational Oncology, Institute for Artificial Intelligence in Medicine, University Hospital Essen, Essen, Germany. ⁹West German Cancer Center, Institute for Pathology, University Hospital Essen, Essen, Germany. ¹⁰West German Cancer Center, Department of Pulmonary Medicine, University Medicine Essen – Ruhrlandklinik, Essen, Germany. ¹¹West German Cancer Center, Department of Dermatology, University Hospital Essen, Essen, Germany. ¹²Laboratory Medicine Department, Laboratory for Molecular Diagnostics, Jessa Hospital, Hasselt, Belgium. ¹³Department of Pathology, Jessa Hospital, Hasselt, Belgium. ¹⁴West German Cancer Center, Department of Nuclear Medicine, University Hospital Essen, Essen, Germany. ¹⁵Department of Surgery, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. ¹⁶University Hospital Frankfurt, Dr Senckenberg Institute of Pathology, Goethe University, Frankfurt, Germany. ¹⁷Department of Thoracic Oncology, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. ¹⁸Present address: University Hospital Carl Gustav Carus, Department of Surgery, Division of Thoracic Surgery, Technical University Dresden, Dresden, Germany. ¹⁹Present address: General Hospital Vienna, Department of Thoracic Surgery, Medical University Vienna, Vienna, Austria. ²⁰These authors contributed equally: Alexander Schramm, Clemens Aigner.

✉e-mail: martin.schuler@uk-essen.de; kristof.cuppens@jessazh.be

Methods

Clinical study

Patients. Adult patients with histologically or cytologically confirmed NSCLC eligible for anatomic resection were enrolled. Clinical stages IB, II and selected stage IIIA (T3 N1, T4 with satellite nodule in the same lung N0/N1, selected T1a–T2b N2 cases considered suitable for primary surgical approach by the multidisciplinary tumor board) according to the Union International Contre le Cancer (UICC) eighth edition were eligible. Additional inclusion criteria (see Supplementary information for full study protocol) are women and men ≥ 18 years of age, Eastern Cooperative Oncology Group performance score ≤ 1 , exclusion of extensive mediastinal lymph node metastases (multilevel N2, N3), exclusion of distant metastases, measurable target tumor before immunotherapy using standard imaging techniques, sufficient pulmonary function to undergo curative lung cancer surgery (percentage of predicted forced expiratory volume at 1 s (ppFEV1) $> 30\%$, percentage of predicted diffusion capacity of the lung for carbon monoxide (ppDLCO) $> 30\%$, percentage of predicted maximal oxygen consumption (ppVO₂max) ≥ 10 ml min⁻¹ kg⁻¹ (if cardiopulmonary exercise testing was mandated per local guidelines)), adequate hematological, hepatic and renal function parameters, sufficient cardiac left ventricular function defined as left ventricular ejection fraction $\geq 50\%$ documented either by echocardiography or multigated acquisition (MUGA) scan, ability and willingness to provide written informed consent and to comply with the study protocol and with the planned surgical procedures. Gender was determined based on self-report.

Exclusion criteria (see Supplementary information for full study protocol) are: active or history of autoimmune disease or immune deficiency; subjects with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration; subjects who have undergone organ transplant or allogeneic stem cell transplantation; ppFEV1 $< 30\%$, ppDLCO $< 30\%$, ppVO₂max < 10 ml min⁻¹ kg⁻¹ (if cardiopulmonary exercise testing was mandated per local guidelines); uncontrolled or significant cardiovascular disease (including myocardial infarction, stroke or transient ischemic attack, uncontrolled angina, clinically significant arrhythmias, QTc prolongation > 480 ms, pulmonary hypertension); history of other clinically significant cardiovascular disease (including cardiomyopathy, congestive heart failure, pericarditis, pericardial effusion, coronary artery stent occlusion, deep venous thrombosis); cardiopulmonary disease-related requirement for daily supplemental oxygen; subjects with a history of myocarditis, regardless of etiology; elevated troponin T or I; active neurological disease; active malignancy or previous malignancy within the past 3 years; known history of positive test for human immunodeficiency virus (HIV-1 and HIV-2) or known acquired immunodeficiency syndrome; any positive test result for hepatitis B virus or hepatitis C virus (HCV) indicating presence of virus, for example hepatitis B surface antigen (Australia antigen) positive or hepatitis C antibody (anti-HCV) positive (except if HCV RNA negative); any other disease, metabolic dysfunction, physical examination finding or clinical laboratory finding that contraindicates the use of an investigational drug, may affect the interpretation of the results or may render the patient at high risk from treatment complications; receipt of live attenuated vaccine within 30 days before the first dose of study medication; peripheral neuropathy National Cancer Institute Common Terminology Criteria for Adverse Events grade ≥ 2 ; history of gastric perforation or fistulae in past 6 months; serious or nonhealing wound, ulcer or bone fracture within 28 days before enrollment; major surgery within 28 days before enrollment except staging mediastinoscopy, diagnostic video-assisted thoracoscopic surgery (VATS) or implantation of a venous port-system; any other concurrent preoperative antineoplastic treatment including irradiation, pregnant or breastfeeding women; insufficient cardiac left ventricular function defined as left ventricular ejection fraction $< 50\%$ by echocardiography or MUGA scan; confirmed

history of encephalitis, meningitis or uncontrolled seizures in the year before informed consent; subjects with a history of severe toxicity or life-threatening toxicity (grade 3 or 4) related to previous immune therapy (for example anti-CTLA-4 or anti-PD-1/PD-L1 treatment or any other antibody or drug specifically targeting T cell co-stimulation or immune checkpoint pathways) except those that are unlikely to reoccur with standard countermeasures (for example, hormone replacement after endocrinopathy); history of severe or life-threatening (grade 3 or 4) infusion-related reactions to previous immunotherapy; previous treatment with LAG-3 targeting agent; participation in another interventional clinical study within the past 3 months before inclusion or simultaneous participation in other clinical studies; previous treatment with nivolumab or relatlimab; previous immunotherapy for lung cancer; criteria that in the opinion of the investigator preclude participation for scientific reasons, for reasons of compliance or for reasons of the subject's safety; or any contraindications against nivolumab or relatlimab.

Study design and treatment. NEOpredict-Lung (NCT04205552) is an open-label, randomized phase 2 trial (see Supplementary information for the version of the study protocol pertinent to this report). This manuscript reports results from arms A and B of the study, which treated patients with two doses of nivolumab (240 mg every 14 days per intravenous infusion, arm A) or nivolumab and relatlimab (240 and 80 mg, respectively, every 14 days per intravenous infusion, arm B). The dose and schedule of nivolumab and nivolumab plus relatlimab were selected to align with the biweekly administration of nivolumab in other studies of preoperative ICI combinations in NSCLC patients, such as NEOSTAR¹⁰ and CheckMate 816 (ref. 13). It is supported by findings of the ongoing study RELATIVITY-020 (ref. 39), which explores multiple doses and schedules of relatlimab-based combinations.

The study was not designed to formally compare both treatment arms. No gender analysis was performed because of the limited cohort sizes and the nature of the study.

Patients were randomly assigned (1:1) via an interactive web response system provided by Alcedis GmbH (<https://www.alcedis.de/en>); there was no stratification or blinding. Patients were treated for a maximum of two cycles (14 days each), which was followed by standard of care surgery and, if clinically indicated, postoperative medical therapy and/or radiotherapy. Surgery and postoperative treatments were not part of the clinical study intervention. All patients are followed up to 12 months within the study protocol. Subsequent follow-up is provided within standard of care.

Endpoints. The primary study endpoint is the number of patients proceeding to curatively intended surgery of NSCLC within 43 days of the initiation of study therapy.

Secondary endpoints include: the objective response rate (RECIST 1.1) before surgery; the pathological response rate (complete pathological responses defined as the absence of viable tumor cells on routine H&E staining of resected tumors and lymph nodes, and rate of MPRs defined as 10% or less viable tumor cells on routine H&E staining of resected tumors); the R0 resection rate; the DFS rate at 12 months per RECIST 1.1; the OS rate at 12 months; the safety and tolerability of preoperative immunotherapy; and morbidity and mortality within 90 days of surgery.

Exploratory endpoints are assessed in tumor and lymph node samples, blood cells, plasma and serum.

All primary and secondary endpoints were assessed in the intention-to-treat population and in the full analysis set.

Clinical data are captured in the clinical database using a proprietary electronic case report system provided by Alcedis GmbH (<https://www.alcedis.de/en>).

Assessments. Radiographic and nuclear imaging assessments at baseline were conducted within standard of care at the study sites. Specifically, all 60 patients underwent whole-body imaging by

FDG-PET/CT. For exclusion of brain metastases, 41 patients underwent contrast-enhanced brain magnetic resonance imaging (MRI) scanning, 18 patients underwent contrast-enhanced brain CT scanning (because of contraindications or intolerance of MRI imaging or unavailability of an MRI slot within the protocol-defined screening period). In one patient with stage IB NSCLC no brain imaging was performed as per Dutch guidelines. All patients underwent CT or PET/CT imaging immediately before surgery. Radiographic response was evaluated at the study sites following RECIST 1.1. Exploratory analyses were conducted on nuclear imaging data acquired before surgery.

Baseline assessments included the collection of tumor tissue samples for centrally performed exploratory analyses. Diagnostic tumor tissue was obtained by endobronchial ultrasound-guided biopsy (31 patients), CT-guided transthoracic biopsy (17 patients) or by other approaches including bronchoscopy-guided forceps biopsy and mini-probe/navigation-guided biopsy (13 patients). For mediastinal staging, 47 patients underwent systematic endobronchial ultrasound including sampling of suspicious lymph nodes, and 11 patients had staging mediastinoscopy.

Histology and biomarker studies were conducted within standard of care at the study sites. PD-L1 expression by tumor cells was assessed locally using the primary antibody clone 22C3 (DAKO/Agilent M3653) following validated protocols with continuous external quality assurance (QUIP, UK NEQAS, NordiQC).

Additional tumor tissue samples were collected during surgery, and blood samples were collected at protocol-defined time points.

Statistical analyses. Based on published results of a study with pre-operative nivolumab⁹ each study arm included up to 30 evaluable patients with the expectation that at least 26 of 30 patients treated in each study arm will undergo curatively intended surgery within 6 weeks of initiation of study treatment. At maximum 4 of 30 patients may experience a delay of curatively intended surgery beyond day 43 (with study treatment being administered on day 1), either because of toxicities or disease progression, to declare the study arm feasible. Continuous monitoring of prespecified stopping boundaries was applied to facilitate early termination of nonfeasible study arms to reduce patient risks. Details can be reviewed in the clinical study protocol (Supplementary information).

All secondary parameters were evaluated in an explorative or descriptive manner, providing means, medians, ranges, standard deviations and/or confidence intervals.

Trial oversight. The protocol and amendments were approved by the responsible ethics committees and competent regulatory authorities at each participating study site and country. In the legislature of the study sponsor and study site Essen the Ethics Committee of the Medical Faculty of the University Duisburg-Essen, Essen, Germany, granted primary approval on 10 September 2019 (19-8828-AF). The competent regulatory authority in the legislature of the study sponsor and study site Essen, the Paul-Ehrlich-Institut (Federal Institute for Vaccines and Biomedicines), Langen, Germany, granted primary approval on 27 November 2019 (EudraCT-Nr. 2109-007278-29, Vorlage-Nr. 3834/01). For study site Hasselt, approval was granted by the Ethics Committee OLV Ziekenhuis VZW, Aalst, Belgium (EudraCT-Nr. 2109-007278-29 Pilot 262-SM001, Reference 202/082), and the Federal Agency for Medicines and Health Products, Brussels, Belgium (EudraCT-Nr. 2109-007278-29 Pilot 262, 1240640 M). For study site Amsterdam, approval was granted by the METC—The Netherlands Cancer Institute, Antoni van Leeuwenhoek (NKI-AVL), Amsterdam, The Netherlands (NL72532.031.20), and by the Centrale Commissie Mensgebonden Onderzoek, The Hague, The Netherlands (Decree NL72532.031.21 CA).

The study was conducted according to the principles of the Declaration of Helsinki and the International Conference on Harmonization Good Clinical Practice guidelines.

All patients provided written informed consent before enrollment. The study is sponsored by the University Hospital Essen and was designed by employees of the sponsor, who were also study investigators.

A data safety monitoring committee, which is independent of the sponsor and the study investigators, reviewed all safety and efficacy data, including radiographic and pathological response data.

The clinical data were collected by the investigators, analyzed by statisticians employed by a contract research organization commissioned by the sponsor, and interpreted by the authors. Authors had full access to the data and are responsible for all content and editorial decisions.

Metabolic hybrid imaging

As per national and international practice guidelines, patients received FDG-PET/CT (or PET) at initial staging. Patients treated at study site Essen underwent a second FDG-PET/CT scan before surgery to confirm curative resectability. Images were acquired at a median of 4 days (range 1–29 days) before surgery. Imaging data were collected on three different PET/CT scanner types (Biograph Vision 600 (Siemens Healthineers), Biograph mCT (Siemens Healthineers), Vereos (Philips Healthcare)). It was ascertained that each individual patient underwent both scans on the same scanner type. Data acquisition started 67 ± 18 min (PET/CT 1) and 72 ± 12 min (PET/CT 2) after injection of 305 ± 58 MBq FDG (PET/CT 1) and 280 ± 58 MBq FDG (PET/CT 2), respectively. Patient handling and data processing were performed as detailed elsewhere⁴⁰. After attenuation correction metabolic response rates were estimated according to PERCIST 1.0 (ref. 28).

Phenotyping of peripheral blood T cells

T cell phenotypes were determined by multiparametric flow cytometry. Briefly, cryopreserved peripheral blood mononuclear cells were thawed and rested overnight in RPMI medium supplemented with 10% FCS, 100 U ml⁻¹ penicillin and 100 µg ml⁻¹ streptomycin (PAA Laboratories) at 37 °C in a 5% CO₂ atmosphere. Antibody staining of cell surface molecules (30 min, 4 °C) was followed by fixation and permeabilization for staining of intracellular markers (30 min, 4 °C). Stained samples were analyzed using a Gallios flow cytometer (Beckman Coulter) and Kaluza software (Beckman Coulter). Antibodies and gating strategy are depicted in Supplementary Fig. 2a.

Phenotyping of immune cell subsets in resected tumors

Dissection of resected tumors. Tumor tissue was put in 1 ml of digestion medium (Dulbecco's modified Eagle's medium/F12/HEPES solution supplemented with penicillin/streptomycin and 1% BSA and containing collagenase, hyaluronidase and DNase I) and cut into small pieces. To facilitate dissociation the tissue was incubated for 40 min at 37 °C and pipetted every 10 min during the incubation period. The resulting cell suspension was transferred to a 50-ml centrifuge tube and centrifuged at 300g for 10 min at ambient temperature. The pellet was resuspended in trypsin/EDTA and incubated for 5 min at ambient temperature. After inactivation of the trypsin by Dulbecco's modified Eagle's medium/F12/HEPES solution containing 10% FCS, the cell suspension was again triturated and filtered through a 40-µm cell strainer. After washing the filter with 50 ml of phosphate-buffered saline (PBS) the cells were centrifuged at 400g for 5 min at ambient temperature. Following one more washing step with PBS, cell number and viability was measured using the NucleoCounter NC-3000 and one to two million cells per vial were cryopreserved in FCS-containing 10% DMSO.

Flow cytometry. The cryopreserved tumor cell suspensions were analyzed in batches using two panels of antibodies. The staining method, antibodies and gating strategy for T lymphocyte subsets (Supplementary Fig. 2b) have been described previously⁴¹. Myeloid immune cells

were detected using a separate antibody panel and gating strategy (Supplementary Fig. 2c). Flow cytometry was run on a CytoFLEX LX (Beckman Coulter) using the CytExpert v.2.3 software. Final data analysis was performed using FlowJo Software v.10 (Tree Star).

Gene expression analyses

RNA isolation and quantification. For nucleic acid isolation, two to four sections each 10- μ m thick (depending on sample size) from the respective formalin-fixed paraffin-embedded (FFPE) tissue sample were used. In total, RNA isolation could be performed on 46 resected tumors as well as 17 paired biopsies. Isolation procedures have been carried out semiautomatically on the Maxwell purification system (Maxwell RSC RNA FFPE Kit; Promega, cat. no. AS1440). All steps were performed following the respective protocol provided by the manufacturer. Total RNA was eluted in 50 μ l RNase-free water and quantified using the RNA broad-range assay on a Qubit 2.0 fluorometer (Life Technology). One microliter of sample isolate volume was diluted for each quantification. RNA was stored at -80°C until further use.

NanoString CodeSet design. Fluorescently barcoded RNA probes were synthesized and provided by NanoString. In total, gene expression was quantified using the dedicated PanCancer Immune Profiling panel as well as the PanCancer Pathway panel. Both panels consisted of the identical 40 reference and 770 individual target genes. The PanCancer Pathway panel comprises key players of the Notch, APC (Wnt), Hedgehog, transforming growth factor β , MAPK, STAT, PI3K and RAS signaling pathways as well as chromatin modification, transcriptional regulation, DNA damage control, cell cycle and apoptosis. The PanCancer Immune Profiling panel comprises targets associated with the various immunological processes and pathways of a host anti-cancer immune response. In total, both panels combined cover 1,398 different genes. For both panels, one sample served as a blank.

Digital gene expression analysis by hybridization. Digital gene expression analysis was performed on the NanoString nCounter platform, utilizing the NanoString MAX/FLEX system. A minimum of 100 ng of total RNA sample input was hybridized to the probes for 21 h at 65°C . Subsequent cartridge preparation was performed in a NanoString PrepStation using the high-sensitivity protocol. Finally, the cartridge was scanned on the DigitalAnalyzer (NanoString) at 555 fields-of-view.

Gene expression analysis. NanoString data was normalized and cleaned using NanoTube (v.1.6.0)⁴², entailing three steps. First, counts were scaled by comparing the geometric mean of positive control features between samples. Second, genes in which at least 50% of samples are <2 s.d. above the mean of negative controls were removed. Third, counts were scaled by comparing the geometric mean of housekeeping genes between samples. Afterwards, differential expression analysis was performed using the quasi-likelihood F -test approach of EdgeR (two-sided, v.3.40.0)⁴³. First, genes differentially expressed between sample types (resected tumor versus biopsy) were determined, while correcting for additive batch effects induced by pathological response (MPR = 1/0) and tumor classification (LUAD, lung squamous cell carcinoma, large-cell neuroendocrine carcinoma, sarcomatoid). Second, genes differentially expressed between MPR and no MPR were determined separately within each sample type and study arm. Reproducibility was ensured by implementing above analysis as a Snakemake⁴⁴ workflow.

Genome sequencing

DNA isolation and quantification. For tumor samples, one to four FFPE sections (10- μ m thick, number depending on sample size) were lysed for genomic DNA isolation. Isolation was performed semiautomatically on

the Maxwell purification system (Maxwell RSC DNA FFPE Kit; Promega, cat. no. AS1450) as specified by the manufacturer. DNA was eluted in 50 μ l of RNase-free water and quantified fluorescently for library preparation using a Qubit 2.0 fluorometer (Life Technology) with its appertaining DNA broad-range assay. Corresponding normal DNA was isolated from blood or peripheral blood mononuclear cells using routinely available QIAGEN technology. DNA was stored at -20°C before use.

Sequencing and genomic variant calling. Whole-exome sequencing was performed using the Twist Human Core + RefSeq + Mitochondrial Panel (Twist Bioscience), and 2×100 -bp fragment sizes were sequenced using a NovaSeq6000 (Illumina). Demultiplexing of sequenced reads was achieved using bcl2fastq (v.2.2). Further data analysis was performed using our open-source Snakemake workflow dna-seq-varlociraptor (v.3.24, <https://github.com/snakemake-workflows/dna-seq-varlociraptor>), entailing the following steps. Adapter trimming was performed using Cutadapt (v.4.1, <https://doi.org/10.14806/ej.17.1.200>). Quality was monitored using MultiQC (v.1.14)⁴⁵ including FASTQC (v.0.11.9, <https://www.bioinformatics.babraham.ac.uk/projects/fastqc/>), Samtools (v.0.2.18)⁴⁶ and samtools (v.1.14)⁴⁷. Reads were mapped to GRCh38 using bwa-mem (v.0.7.17, <https://doi.org/10.48550/arXiv.1303.3997>) and deduplicated using Picard-Tools (v.2.26). Base qualities were recalibrated using GATK (v.4.2)⁴⁸. Single nucleotide variants and small indels were detected using Freebayes (v.1.3.6, <https://doi.org/10.48550/arXiv.1207.3907>) and classified into events of interest (somatic in biopsy or resection, germline) using Varlociraptor (v.8.3)⁴⁹. Variant calls were distinguished from noise by controlling the (Bayesian) local false discovery rate (FDR) using Varlociraptor. Variant annotation (with impact, previous knowledge) was performed using VEP (v.109.3)⁵⁰. Extraction of variants of interest was performed using vembrane (v.1.0)⁵¹. Specifically, for Fig. 2a, variants were filtered to be nonsynonymous, having a REVEL score >0.5 if available (that is, being predicted as pathogenic), having a gnomad allele frequency <0.2 , being not marked as benign or likely benign in ClinVar and impacting one of the TCGA LUAD 500 cancer genes. Missing whole-exome sequencing data was complemented with results from panel sequencing (TSO500) whenever available. To identify genes that had altered variant allele frequencies (VAFs) comparing the diagnostic biopsy and the resected tumor, genes defined by oncoPrint (<https://www.oncoprint.org/cancer-genes>) were inspected. To adjust for the different tumor cell content between biopsies and resected tumors, probabilities were calculated that the variants were not present in the normal sample of the same patient and that the VAF had changed before surgery. Only variants that were not marked by ClinVar as benign or likely benign and had a REVEL score >0.7 are reported in Supplementary Fig. 3.

Inference of subclonal diversity

Tumor purity estimation. Previous estimates p_1 and p_2 of the tumor purity of samples from resected tumors were obtained by two independent pathologists evaluating sections stained with H&E. For the other samples, a posterior estimate of the tumor purity of each sample was obtained as follows. We plotted the somatic VAF distribution of the pretherapeutic biopsy and the resected tumor samples of each patient. For this, the maximum a posteriori allele frequency estimates provided by Varlociraptor without adjusting for purity were used (that is, no sample contamination assigned, see <https://varlociraptor.github.io/docs/calling>). The expectation is that without copy number variants any somatic variant may at most have a VAF equal to the tumor purity. Read sampling variance and copy number variation can generate peaks beyond the tumor purity. For resection samples, we proceeded as follows: Let ν be the highest VAF of the distribution or a threshold for which higher VAFs could as well be explained by sampling or copy number variation. If ν was consistent with the previous estimates (that is, within the interval $[p_1, p_2]$) and the previous estimates were agreeing

to a sufficient degree ($p_2 - p_1 \leq 0.2$) we reported ν as the posterior purity. Otherwise, we considered the posterior purity as unknown (28 of 56 cases). For samples in which the resected tumor had a posterior purity, we compared the distribution of the pretherapeutic biopsy and the resected tumor, and inferred a posterior estimate by scaling the biopsy distribution to match the shape of the resection distribution. Such scaling was possible in all investigated cases.

Subclonal diversity. For patients with posterior purity estimates, subclonal diversity was visualized in the following way. During tumor evolution, each somatic mutation that does not lead to cell death can be seen as an event generating a new subclone. We made the simplifying assumption that each nonlethal somatic mutation during development of the tumor generates one new subclone. Thus, the number of somatic variants can be seen as a proxy for the number of subclones, and each somatic variant can be considered as a representative of the subclone that originates in it. Note that this neglects the fact that multiple somatic variants can occur during one cell division. However, under the assumption that all considered samples have a similar somatic mutation rate, the subclone counts obtained would still be proportional to the true number of subclones, and thereby comparable across patients.

Thus, for each patient, we obtained the sufficiently relevant subclones by considering variants with posterior probability ≥ 0.95 according to Varlociraptor for being somatic in the pretreatment biopsy or in the resected tumor, and purity adjusted VAF ≥ 0.1 . To be able to be certain that a variant is detectable in both the pretreatment biopsy and the resected tumor, we further filtered them such that there would be an expectation that they would be represented by at least two reads if occurring at the same frequency in the respective other sample (pretreatment biopsy for resected tumor; resected tumor for pretreatment biopsy). Patients in whom both pretreatment biopsy and resected tumor had no such somatic variants/subclones after filtering were omitted because they would not allow any statement about subclonal gains and losses. Variants with VAF = 0.0 in the resected tumor but VAF ≥ 0.1 in the pretreatment biopsy were then counted as ‘lost subclones’ following study therapy. Variants with VAF = 0.0 in the pretreatment biopsy but VAF ≥ 0.1 in the resected tumor were counted as ‘gained subclones’ following study therapy. Note that because the pretreatment biopsy may not represent the entire primary tumor, a ‘gain’ is not distinguishable from enrichment of a variant that was spatially missed in the biopsy.

Reporting summary

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

Data availability

The study protocol is provided with the Supplementary Information. Once the study is formally completed, a Clinical Study Report with tabulated data listings is prepared, which will be considered for sharing upon request from qualified scientists, if there is legal authority to share the data and there is no likelihood of participant re-identification. De-identified raw data from gene expression profiling and whole-exome sequencing have been deposited in the European Genome-Phenome Archive (EGA) with accession number [EGAS00001007753](https://ega-archive.org/studies/EGAS00001007753). Requests should be submitted to the Office of Data Governance of the study sponsor, University Hospital Essen (<https://www.uk-essen.de/>), which also serves as Data Access Committee (DAC). Responses can be expected within 4 weeks.

Code availability

All code developed and used in this study is open source. The Snake-make workflows for whole-exome sequencing analysis and NanoString nCounter gene expression analysis can be found at <https://zenodo.org/records/10838511> (ref. 52) and <https://zenodo.org/doi/10.5281/zenodo.10838907> (ref. 53).

References

39. Ascierto, P. A. et al. Nivolumab and relatlimab in patients with advanced melanoma that had progressed on anti-Programmed Death-1/Programmed Death Ligand 1 therapy: results from the phase I/IIa RELATIVITY-020 trial. *J. Clin. Oncol.* **41**, 2724–2735 (2023).
40. Hautzel, H. et al. N-staging in large cell neuroendocrine carcinoma of the lung: diagnostic value of [(18)F]FDG PET/CT compared to the histopathology reference standard. *EJNMMI Res.* **11**, 68 (2021).
41. Westhölter, D. et al. Regulatory T cell enhancement in adults with cystic fibrosis receiving elxacaftor/tezacaftor/ivacaftor therapy. *Front. Immunol.* **14**, 1107437 (2023).
42. Class, C. A., Lukan, C. J., Bristow, C. A. & Do, K. A. Easy NanoString nCounter data analysis with the NanoTube. *Bioinformatics* **39**, btac762 (2023).
43. Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. *Bioinformatics* **26**, 139–140 (2010).
44. Mölder, F. et al. Sustainable data analysis with Snakemake. *F1000Res.* **10**, 33 (2021).
45. Ewels, P., Magnusson, M., Lundin, S. & Käller, M. MultiQC: summarize analysis results for multiple tools and samples in a single report. *Bioinformatics* **32**, 3047–3048 (2016).
46. Pedersen, B. S. et al. Somalier: rapid relatedness estimation for cancer and germline studies using efficient genome sketches. *Genome Med.* **12**, 62 (2020).
47. Danecek, P. et al. Twelve years of SAMtools and BCFtools. *Gigascience* **10**, giab008 (2021).
48. DePristo, M. A. et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. *Nat. Genet.* **43**, 491–498 (2011).
49. Köster, J., Dijkstra, L. J., Marschall, T. & Schönhuth, A. Varlociraptor: enhancing sensitivity and controlling false discovery rate in somatic indel discovery. *Genome Biol.* **21**, 98 (2020).
50. McLaren, W. et al. The Ensembl Variant Effect Predictor. *Genome Biol.* **17**, 122 (2016).
51. Hartmann, T., Schröder, C., Kuthe, E., Lähnemann, D. & Köster, J. Insane in the vembrane: filtering and transforming VCF/BCF files. *Bioinformatics* **39**, btac810 (2023).
52. Lähnemann, D. & Köster, J. Snakemake workflow: WES analysis ‘Neoadjuvant nivolumab with or without relatlimab in resectable non-small cell lung cancer: an open-label, randomized phase II trial’. *Zenodo* <https://zenodo.org/records/10838511> (2024).
53. Lähnemann, D. & Köster, J. Snakemake workflow: Nanostring analysis for ‘Neoadjuvant nivolumab with or without relatlimab in resectable non-small cell lung cancer: an open-label, randomized phase II trial’. *Zenodo* <https://zenodo.org/doi/10.5281/zenodo.10838907> (2024).

Acknowledgements

We thank the patients and their families who participated in the NEOpredict-Lung study, and all staff involved in patient care, study management and translational research at University Medicine Essen, Jessa Hospital and Antoni van Leeuwenhoek Hospital. The West German Biobank Essen (wbe) is acknowledged for supporting study biobanking and biomarker analyses, and the University Medicine Essen Study Center GmbH (UME SZ) for supporting sponsor oversight and project management. S. Reuter contributed to phenotyping of tumor-infiltrating immune cells. Bristol Myers Squibb is sincerely thanked for providing the study medication and institutional grant support (grant no. CA224-063). The West German Cancer Center Essen is supported by Oncology Center of Excellence grants from the German Cancer Aid (Deutsche Krebshilfe) and receives federal and state funding as National Center for Tumor Diseases (NCT) West and as partner site of the German Cancer Consortium (DKTK). The funding sources had no influence on the manuscript.

Author contributions

M.S. and C.A. designed the study, wrote and amended the study protocol, and were the principal investigators of the trial in general and at the West German Cancer Center Essen. K.C. was the principal investigator at Jessa Hospital Hasselt. P.B. was the principal investigator at the Netherlands Cancer Institute Amsterdam. M.S., K.C., T.P., M.W., B.D.P., K.D., K.H., P.B. and C.A. were involved in study patient care and supervised data acquisition. A.S. supervised the study-associated translational research program. H.H. was responsible for functional imaging and PERCIST evaluation. B.M., M.V., D.T. and H.R. were responsible for histopathology and molecular pathology. B.H., A.P. and F.Z. supervised and conducted immunological analyses. J.K., F.M., D.L. and A.S. supervised and conducted genomic and gene expression studies. J.K. developed and applied novel bioinformatic technology. M.S., B.H., J.K., A.P. and A.S. interpreted the translational data. M.S. wrote the manuscript, which was reviewed, edited and approved by all authors. The authors are personally accountable for their own contributions, the accuracy and data integrity, and the overall conclusions of the manuscript. No medical writer was involved at any stage of the preparation of this manuscript.

Funding

Open access funding provided by Universität Duisburg-Essen.

Competing interests

M.S., K.C., B.H., J.K., F.M., A.P., B.M., H.R., P.B., A.S. and C.A. received institutional funding, paid to the University Hospital Essen, from Bristol Myers Squibb to support the study NEOpredict-Lung. The following authors declare potential conflicts of interest: M.S. (Fees for consulting from Amgen, AstraZeneca, Blueprint Medicines, Boehringer Ingelheim, Bristol Myers Squibb, GSK, Janssen, MSD, Novartis, Roche, Sanofi and Tacalyx; honoraria for CME presentations from Amgen, Bristol Myers Squibb, GSK, Janssen, MSD, Roche and Sanofi; institutional research funding to University Hospital Essen from AstraZeneca, Bristol Myers Squibb and Janssen); K.C. (Fees for consulting from AstraZeneca/Medimmune, Bayer, Bristol Myers Squibb, MSD; institutional research funding from Bristol Myers Squibb; travel support from MSD; other relationship to Bristol Myers Squibb); M.W. (Fees for consulting from Daiichi Sankyo, Janssen, Novartis, Pfizer and Roche; honoraria for CME presentations from Amgen, AstraZeneca, GSK, Janssen, Novartis, Roche and Takeda; institutional research funding to University Hospital Essen from Bristol Myers Squibb and Takeda; travel support from Amgen and Bristol Myers Squibb); B.H. (institutional research funding to University Hospital Essen from Bristol Myers Squibb),

K.D. (Fees for consulting from BMS, Boehringer Ingelheim, Boston Scientific, Broncus Medical, FreeFlow, Fujifilm, Lys Medical, Medtronic, Morair Medtech, Olympus, Pulmonx and Storz; honoraria for CME presentations from AstraZeneca, Boehringer Ingelheim, Boston Scientific, Broncus Medical, Erbe Elektromedizin, Olympus and Storz; institutional research funding to University Medicine Essen – Ruhrlandklinik from Ambu, Broncus Medical, Epigenomics, Gala Therapeutics, Novartis, NuVaira, PneumRx, Pulmonx and Roche); H.H. (Honoraria for CME presentations from Urenco; travel support from Pari; institutional research funding to University Hospital Essen from Pari), H.R. (Honoraria for CME presentations from AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Chop GmbH, Diaceutics, GSK, HUG, Janssen-Cilag, MCI, Merck, Novartis, Roche Pharma, Sanofi and Wolfsburg Klinikum; institutional research funding from Bristol Myers Squibb), P.B. (Fees for consulting from AstraZeneca, Beigene, Bristol Myers Squibb, Merck Sharp & Dohme; honoraria from Bristol Myers Squibb, MSD; research funding to the Netherlands Cancer Institute from Bristol Myers Squibb; travel support from MSD; other relationship to Bristol Myers Squibb), A.S. (Institutional research funding to University Hospital Essen from Bristol Myers Squibb) and C.A. (Fees for consulting from Ewimed; honoraria for CME presentations from AstraZeneca, Bristol Myers Squibb, Roche; institutional research funding to University Hospital Essen Bristol Myers Squibb, and to University Medicine Essen – Ruhrlandklinik from PharmaCept). The other authors declare no competing interests.

Additional information


Extended data is available for this paper at <https://doi.org/10.1038/s41591-024-02965-0>.

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41591-024-02965-0>.

Correspondence and requests for materials should be addressed to Martin Schuler or Kristof Cuppens.


Peer review information *Nature Medicine* thanks Justin Gainor and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Primary Handling Editor: Ulrike Harjes, in collaboration with the *Nature Medicine* team.

Reprints and permissions information is available at www.nature.com/reprints.



Extended Data Fig. 1 | Response assessment per FDG-PET/CT and CT in relation to pathological response and nodal upstaging. Metabolic responses (PERCIST), radiographic responses (RECIST), nodal upstaging (yes, no), pathological response category (Viable tumor cells), and treatment arm

(A – nivolumab, B – nivolumab/relatlimab) of 30 patients from study site Essen, who underwent FDG-PET/CT scanning following preoperative immunotherapy. One patient was excluded because surgery was aborted due to pleural carcinosis.



Extended Data Fig. 2 | See next page for caption.

Extended Data Fig. 2 | Immune cell subsets in peripheral blood and resected tumors. a, Induction of CD8+GrzB+ effector T cells in the peripheral blood in response to neoadjuvant nivolumab or nivolumab and relatlimab treatment. Each dot represents an individual patient, base line values in black, values at day 28 (after neoadjuvant immunotherapy) in red. Responders are defined by $\leq 50\%$ viable tumor cells in resected tumors and lymph nodes, non-responders by $>50\%$ viable tumor cells. The Wilcoxon matched pairs signed-rank test was applied for statistical comparison. All p-values are two-sided, no adjustment was made

for multiple comparisons. **b,** Characterization of infiltrating T lymphocytes in resected tumors in relation to study treatment (arm A: nivolumab, arm B: nivolumab and relatlimab) and achieving a major pathological response (MPR, $\leq 10\%$ viable tumor cells in resected tumors and lymph nodes) or not achieving a MPR (no MPR). Each symbol represents an individual patient. Tregs – regulatory T lymphocytes. Horizontal lines indicate the mean value and standard error of the mean.

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a	Confirmed
<input type="checkbox"/>	<input checked="" type="checkbox"/> The exact sample size (<i>n</i>) for each experimental group/condition, given as a discrete number and unit of measurement
<input type="checkbox"/>	<input checked="" type="checkbox"/> A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
<input type="checkbox"/>	<input checked="" type="checkbox"/> The statistical test(s) used AND whether they are one- or two-sided <i>Only common tests should be described solely by name; describe more complex techniques in the Methods section.</i>
<input type="checkbox"/>	<input checked="" type="checkbox"/> A description of all covariates tested
<input type="checkbox"/>	<input checked="" type="checkbox"/> A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
<input type="checkbox"/>	<input checked="" type="checkbox"/> A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
<input type="checkbox"/>	<input checked="" type="checkbox"/> For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>
<input checked="" type="checkbox"/>	<input type="checkbox"/> For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
<input type="checkbox"/>	<input checked="" type="checkbox"/> For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
<input checked="" type="checkbox"/>	<input type="checkbox"/> Estimates of effect sizes (e.g. Cohen's <i>d</i> , Pearson's <i>r</i>), indicating how they were calculated

Our web collection on [statistics for biologists](#) contains articles on many of the points above.

Software and code

Policy information about [availability of computer code](#)

Data collection	Clinical data was collected at the study sites using the respective hospital information system. Clinical data were captured in the clinical database using a proprietary electronic Case Report System provided by Alcedis GmbH (https://www.alcedis.de/en), which serves as subcontractor of the sponsor.
Data analysis	<p>All descriptive statistical analyses of clinical study data were performed by Alecdis GmbH using SAS statistical software (version 9.4).</p> <p>Gene expression analysis Nanostring data was normalized and cleaned using NanoTube (version 1.6.0), entailing three steps. First, counts were scaled by comparing the geometric mean of positive control features between samples. Secondly, genes where at least 50% of samples are less than 2 standard deviations above the mean of negative controls were removed. Thirdly, counts were scaled by comparing the geometric mean of housekeeping genes between samples. Afterwards, differential expression analysis was performed using the quasi-likelihood F-test approach of EdgeR (two-sided, version 3.40.0). First, genes differentially expressed between sample types (resected tumor vs. biopsy) were determined, while correcting for additive batch effects induced by pathological response (MPR=1/0) and tumor classification (LUAD, LUSC, LCNEC, sarcomatoid). Secondly, genes differentially expressed between MPR and no MPR were determined separately within each sample type and study arm. Reproducibility was ensured by implementing above analysis as a Snakemake workflow.</p> <p>Genomic variant calling Demultiplexing of sequenced reads was achieved using bcl2fastq (version 2.2). Further data analysis was performed using our open-source Snakemake workflow dna-seq-varlociraptor (version 3.24, https://github.com/snakemake-workflows/dna-seq-varlociraptor), entailing the following steps. Adapter trimming was performed using Cutadapt (version 4.1, https://doi.org/10.14806/ej.17.1.200). Quality was monitored using MultiQC (version 1.14) including FASTQC (version 0.11.9, https://www.bioinformatics.babraham.ac.uk/projects/fastqc/), Somalier</p>

(version 0.2.1846), and samtools (version 1.1447). Reads were mapped to GRCh38 using bwa-mem (version 0.7.17, <https://doi.org/10.48550/arXiv.1303.3997>) and deduplicated using Picard-Tools (version 2.26). Base qualities were recalibrated using GATK (version 4.2). Single nucleotide variants (SNV) and small indels were detected using Freebayes (version 1.3.6, <https://doi.org/10.48550/arXiv.1207.3907>) and classified into events of interest (somatic in biopsy or resection, germline) using Varlociraptor (version 8.3). Variant calls were distinguished from noise by controlling the (Bayesian) local false discovery rate using Varlociraptor. Variant annotation (with impact, prior knowledge) was performed using VEP (version 109.3). Extraction of variants of interest was performed using vembrane (version 1.0). Specifically, for Figure 2 a, variants were filtered to be non-synonymous, having a REVEL score > 0.5 if available (i.e. being predicted as pathogenic), having a gnomad allele frequency < 0.2, being not marked as benign or likely benign in ClinVar and impacting one of the TCGA LUAD 500 cancer genes. Missing WES data was complemented with results from panel sequencing (TSO500) whenever available. To identify genes that had altered variant allele frequencies (VAFs) comparing the diagnostic biopsy and the resected tumor, genes defined by oncoPrint (<https://www.oncoprint.org/cancer-genes>) were inspected. To adjust for the different tumor cell content between biopsies and resected tumors, probabilities were calculated that the variants were not present in the normal sample of the same patient and that the VAF had changed prior to surgery. Only variants that were not marked by ClinVar as benign or likely benign and had a REVEL score > 0.7 are reported in Supplementary Figure 3.

Inference of subclonal diversity

Tumor purity estimation

Prior estimates p_1 and p_2 of tumor purity of samples from resected tumors were obtained by two independent pathologists evaluating sections stained with hematoxylin and eosin (H&E). For the other samples, a posterior estimate of the tumor purity of each sample was obtained as follows: We plotted the somatic variant allele frequency (VAF) distribution of the pretherapeutic biopsy and the resected tumor samples of each patient. For this, the maximum a posteriori allele frequency estimates provided by Varlociraptor without adjusting for purity were used (i.e. no sample contamination assigned, see <https://varlociraptor.github.io/docs/calling>). The expectation is that without copy number variants any somatic variant may at most have a VAF equal to the tumor purity. Read sampling variance and copy number variation can generate peaks beyond the tumor purity. For resection samples, we proceeded as follows: Let v be the highest VAF of the distribution or a threshold for which higher VAFs could as well be explained by sampling or copy number variation. If v was consistent with the prior estimates (i.e. within the interval $[p_1, p_2]$) and the prior estimates were agreeing to a sufficient degree ($p_2 - p_1 \leq 0.2$) we reported v as the posterior purity. Otherwise, we considered the posterior purity as unknown (28/56 cases). For samples where the resected tumor had a posterior purity, we compared the distribution of the pretherapeutic biopsy and the resected tumor, and inferred a posterior estimate by scaling the biopsy distribution to match the shape of the resection distribution. Such scaling was possible in all investigated cases.

Subclonal diversity

For patients with posterior purity estimates, subclonal diversity was visualized in the following way: During tumor evolution, each somatic mutation that does not lead to cell death can be seen as an event generating a new subclone. We made the simplifying assumption that each non-lethal somatic mutation during development of the tumor generates one new subclone. Thus, the number of somatic variants can be seen as a proxy for the number of subclones, and each somatic variant can be considered as a representative of the subclone that originates in it. Note that this neglects the fact that multiple somatic variants can occur during one cell division. However, under the assumption that all considered samples have a similar somatic mutation rate, the subclone counts obtained would still be proportional to the true number of subclones, and thereby comparable across patients.

Thus, for each patient, we obtained the sufficiently relevant subclones by considering variants with posterior probability ≥ 0.95 according to Varlociraptor for being somatic in the pretreatment biopsy or in the resected tumor, and purity adjusted variant allele frequency ≥ 0.1 . For being able to be certain that a variant is detectable in both, the pretreatment biopsy and the resected tumor, we further filtered them such that they would be in expectation represented by at least 2 reads if occurring at the same frequency in the respective other sample (pretreatment biopsy for resected tumor; resected tumor for pretreatment biopsy). Patients where both, pretreatment biopsy and resected tumor, had no such somatic variants/subclones after filtering were omitted as they would not allow any statement about subclonal gains and losses. Then, variants with VAF = 0.0 in the resected tumor but VAF ≥ 0.1 in the pretreatment biopsy were counted as "lost subclones" following study therapy. Variants with VAF = 0.0 in the pretreatment biopsy but VAF ≥ 0.1 in the resected tumor were counted as "gained subclones" following study therapy. Note that since the pretreatment biopsy may not represent the entire primary tumor, a "gain" is not distinguishable from an enrichment of a variant that was spatially missed in the biopsy.

References:

- Class, C.A., Lukan, C.J., Bristow, C.A. & Do, K.A. Easy NanoString nCounter data analysis with the NanoTube. *Bioinformatics* 39, btac762 (2023).
- Robinson, M.D., McCarthy, D.J. & Smyth, G.K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. *Bioinformatics* 26, 139-140 (2010).
- Mölder, F., et al. Sustainable data analysis with Snakemake. *F1000Res* 10, 33 (2021).
- Ewels, P., Magnusson, M., Lundin, S. & Käller, M. MultiQC: summarize analysis results for multiple tools and samples in a single report. *Bioinformatics* 32, 3047-3048 (2016).
- Pedersen, B.S., et al. Somalier: rapid relatedness estimation for cancer and germline studies using efficient genome sketches. *Genome Med* 12, 62 (2020).
- Danecek, P., et al. Twelve years of SAMtools and BCFtools. *Gigascience* 10, giab008 (2021).
- DePristo, M.A., et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. *Nat Genet* 43, 491-498 (2011).
- Köster, J., Dijkstra, L.J., Marschall, T. & Schönhuth, A. Varlociraptor: enhancing sensitivity and controlling false discovery rate in somatic indel discovery. *Genome Biol* 21, 98 (2020).
- McLaren, W., et al. The Ensembl Variant Effect Predictor. *Genome Biol* 17, 122 (2016).
- Hartmann, T., Schröder, C., Kuthe, E., Lähnemann, D. & Köster, J. Insane in the vembrane: filtering and transforming VCF/BCF files. *Bioinformatics* 39, btac810 (2023).

All code developed and used in this study is open source. The Snakemake workflows for whole exome sequencing analysis and NanoString nCounter gene expression analysis can be found under the DOIs 10.5281/zenodo.10838511 and 10.5281/zenodo.10838908.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio [guidelines for submitting code & software](#) for further information.

Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our [policy](#)

The study protocol is provided with the supplemental materials. Once the study is formally completed, a Clinical Study Report with tabulated data listings is prepared, which will be considered for sharing upon request from qualified scientists, if there is legal authority to share the data and there is no likelihood of participant re-identification. De-identified raw data from gene expression profiling and whole exome sequencing have been deposited in the European Genome-Phenome Archive (EGA) with accession number EGAS00001007753. Requests should be submitted to the Office of Data Governance of the study sponsor, University Hospital Essen (<https://www.uk-essen.de/>), which also serves as Data Access Committee (DAC). Responses can be expected within 4 weeks.

Research involving human participants, their data, or biological material

Policy information about studies with [human participants or human data](#). See also policy information about [sex, gender \(identity/presentation\), and sexual orientation](#) and [race, ethnicity and racism](#).

Reporting on sex and gender	To describe the patient cohort, sex and gender is reported using the declaration of each study subject. This represent the sex and gender the respective study subject identifies herself or himself with.
Reporting on race, ethnicity, or other socially relevant groupings	Not applicable.
Population characteristics	The patient population is described in the manuscript and in the study protocol, which is provided with the supplemental material. In brief, adult patients (age above 18 years) with histologically or cytologically confirmed non-small cell lung cancer (NSCLC) eligible for anatomic resection, with the following specifications: Clinical stages I A3, I B, II and selected stage III A (T3 N1, T4 with satellite nodule in the same lung N0/N1, selected T1a-T2b N2 cases considered suitable for primary surgical approach by the multidisciplinary tumor board) according to UICC 8th edition.
Recruitment	Study patients were recruited from the patient populations of the study sites, which reflect the full spectrum of the populations of the three cities and regions. Patients potentially eligible according to the study inclusion and exclusion criteria were offered trial participation by the principal investigators or their delegates at the three enrolling sites. No additional measures were in place to exclude selection bias.
Ethics oversight	The study was approved by the responsible ethics committees and competent regulatory authorities at each participating study site and country. In the legislature of the study sponsor and study site Essen the Ethics Committee of the Medical Faculty of the University Duisburg-Essen, Essen, Germany, granted primary approval on September 10, 2019 (19-8828-AF). The competent regulatory authority in the legislature of the study sponsor and study site Essen, the Paul-Ehrlich-Institut (Federal Institute for Vaccines and Biomedicines), Langen, Germany, granted primary approval on November 27, 2019 (EudraCT-Nr. 2109-007278-29, Vorlage-Nr. 3834/01). For study site Hasselt, approval was granted by the Ethics Committee OLV Ziekenhuis VZW, Aalst, Belgium (EudraCT-Nr. 2109-007278-29 Pilot 262-SM001, Reference 202/082), and the Federal Agency for Medicines and Health Products, Brussels, Belgium (EudraCT-Nr. 2109-007278-29 Pilot 262, 1240640 M). For study site Amsterdam, approval was granted by the METC - The Netherlands Cancer Institute, Antoni van Leeuwenhoek (NKI-AVL), Amsterdam, The Netherlands (NL72532.031.20), and by the Centrale Commissie Mensgebonden Onderzoek, The Hague, The Netherlands (Decree NL72532.031.21 CA).

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

☒ Life sciences ☐ Behavioural & social sciences ☐ Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	Based on published results of a study with preoperative nivolumab each study arm included up to 30 evaluable patients with the expectation that at least 26 of 30 patients treated in each study arm will undergo curatively intended surgery within 6 weeks of initiation of study treatment. At maximum 4 of 30 patients may experience a delay of curatively intended surgery beyond day 43 (with study treatment being administered on day 1), either due to toxicities or disease progression, to declare the study arm feasible. Continuous monitoring of prespecified stopping boundaries was applied to facilitate early termination of non-feasible study arms to reduce patient risks. Further details can be reviewed in the clinical study protocol (Supplementary information).
-------------	--

Reference:

Forde, P.M., et al. Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. N Engl J Med 378, 1976-1986 (2018).

Data exclusions	No data were excluded from this report. One patient could not be analyzed for secondary and exploratory endpoints as curatively intended resection was not performed due to intraoperative detection of pleural carcinosis. Details are presented in the article.
Replication	Per protocol this study prospectively enrolls up to 30 patients per treatment arm. This may be viewed as "30 replicates" of the respective study intervention.
Randomization	Randomization was performed by Alcedis GmbH (https://www.alcedis.de/en), which serves as subcontractor of the sponsor, using a computer system. No stratification was applied.
Blinding	As this is a non-comparative study, blinding is not required.

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems

n/a	Involved in the study
<input type="checkbox"/>	<input checked="" type="checkbox"/> Antibodies
<input checked="" type="checkbox"/>	<input type="checkbox"/> Eukaryotic cell lines
<input checked="" type="checkbox"/>	<input type="checkbox"/> Palaeontology and archaeology
<input checked="" type="checkbox"/>	<input type="checkbox"/> Animals and other organisms
<input type="checkbox"/>	<input checked="" type="checkbox"/> Clinical data
<input checked="" type="checkbox"/>	<input type="checkbox"/> Dual use research of concern
<input checked="" type="checkbox"/>	<input type="checkbox"/> Plants

Methods

n/a	Involved in the study
<input checked="" type="checkbox"/>	<input type="checkbox"/> ChIP-seq
<input type="checkbox"/>	<input checked="" type="checkbox"/> Flow cytometry
<input checked="" type="checkbox"/>	<input type="checkbox"/> MRI-based neuroimaging

Antibodies

Antibodies used

Therapeutic antibodies:

The investigational medical products, nivolumab and relatlimab, were provided by the manufacturer, Bristol Myers Squibb. During the conduct of the study, nivolumab was globally approved for patient treatment in several cancer entities including non-small-cell lung cancer. Relatlimab was still an investigational agent, but has since been approved for the treatment of patients with melanoma. All relevant information was provided by the investigator brochures of nivolumab and relatlimab, which were regularly updated by the manufacturer, and approved by the respective regulatory authorities.

Diagnostic antibodies:

PD-L1: supplier name: Dako, catalog number: M3653, clone name: 22C3, lot number: 11221493, platform: Ventana Benchmark Ultra, antigen retrieval: boiling in CC1 48 min, incubation with primary antibody: 1:40 for 60 min, Optiview detection system

CD8: supplier name: Dako, catalog number: M7103, clone name: C8/144B, lot number: 20055137, platform: Ventana Benchmark Ultra, antigen retrieval: boiling in CC1 40 min, incubation with primary antibody: 1:150 for 24 min, Optiview detection system

Antibody panel for detecting CD8 T cells in peripheral blood:

Antibody	Fluorochrome	Clone	Isotype	Dilution	Source	Catalog#
CD3	ECD	UCHT1	Mouse IgG1, k	1:50	Beckman-Coulter	A07748
CD4	AF700	OKT4	Mouse IgG2b, k	1:100	BioLegend	317425
CD8	APC/Cy7	SK1	Mouse IgG1, k	1:100	BioLegend	344713
GrzB	BV421	QA18A28	Rat IgG1, k	1:200	BioLegend	396413

Antibody panel for myeloid immune cell populations in tumor tissue cell suspensions:

Antibody	Fluorochrome	Clone	Isotype	Dilution	Source	Catalog#	LOT #
CD11c	BV650	3.9	Mouse IgG1, k	1:100	Biolegend	301637	B329910
HLA-DR	BV421	L243	Mouse IgG2, k	1:100	Biolegend	307635	B360315
CD4	Per CP/Cy5.5	RPA-T4	Mouse IgG1, k	1:200	Biolegend	300529	B313462
CD3	AF700	UCHT1	Mouse IgG1, k	1:200	Biolegend	300424	B363398
CD8	BV510	SK1	Mouse IgG1, k	1:200	Biolegend	344731	B293257
CD66b	PE	6/40C	Mouse IgG1, k	1:100	Biolegend	392903	B340558
CD19	PE/Cy 7	H1B19	Mouse IgG1, k	1:100	Biolegend	302216	B368441
CD24	APC	ML5	Mouse IgG2a, k	1:100	Biolegend	311117	B333887
CD206	BV605	15-2	Mouse IgG1, k	1:100	Biolegend	321119	B342527
CD123	PE/Cy5	6H6	Mouse IgG1, k	1:200	Biolegend	306008	B281793

CD56	PE/Dazzle594	HCD56	Mouse IgG1, k	1:200	Biolegend	318347	B315298
CD16	APC/Fire750	3G8	Mouse IgG1, k	1:200	Biolegend	302059	B370797
CD14	BV785	M5E2	Mouse IgG2, k	1:200	Biolegend	301839	B360456
CD45	AF488	2D1	Mouse IgG1, k	1:250	Biolegend	368536	B324537

Antibody panel for T-cell immune cell populations in tumor tissue cell suspensions:

Antibody	Fluorochrome	Clone	Isotype	Dilution	Source	Catalog#	LOT #
CD3	AF700	SK7	Mouse IgG1, k	1:100	Biolegend	300424	B363398
CD4	PerCP/Cy 5.5	RPA-T4	Mouse IgG1, k	1:100	Biolegend	300529	B313462
CD196	BV650	G034E3	Mouse IgG2b, k	1:100	Biolegend	353426	B318067
CD39	BV605	A1	Mouse IgG1, k	1:100	Biolegend	328236	B339983
CD25	BV421	BC96	Mouse IgG1, k	1:100	Biolegend	302630	B365978
CD127	APC	A019D5	Mouse IgG1, k	1:100	Biolegend	351316	B366604
CD8	BV510	SK1	Mouse IgG1, k	1:100	Biolegend	344732	B362160
CD183	BV785	G825H7	Mouse IgG1, k	1:100	Biolegend	353737	B361913
CD194	PE/Dazzle594	L291H4	Mouse IgG1, k	1:100	Biolegend	359420	B359566
CD45	AF488	2D1	Mouse IgG1, k	1:200	Biolegend	368535	B353778
CD19	PE/Cy 7	H1B19	Mouse IgG1, k	1:100	Biolegend	302216	B368441

Validation

Therapeutic antibodies:

All relevant information for nivolumab and relatlimab can be obtained in the Summary of Product Characteristics (SmpC) provided by the manufacturer, Bristol Myers Squibb. In addition, investigator brochures (IB) of nivolumab and relatlimab were provided to the investigators, which were regularly updated by the manufacturer, and approved by the respective regulatory authorities.

Diagnostic antibodies:

All diagnostic antibodies were commercially available and were applied according to the manufacturers' instructions as detailed above. Validation was performed per DIN EN ISO/IEC 17020 / ISO 15189 criteria. On-slide positive controls were used throughout on every slide.

Clinical data

Policy information about [clinical studies](#)

All manuscripts should comply with the ICMJE [guidelines for publication of clinical research](#) and a completed [CONSORT checklist](#) must be included with all submissions.

Clinical trial registration

Study protocol

Data collection

Outcomes

The primary study endpoint is the number of patients undergoing curatively intended surgery of non-small cell lung cancer within 43 days of initiation of study therapy.

Secondary endpoints include:

- Objective response rate (RECIST 1.1) prior to surgery
- Pathological response rate (complete pathological responses defined as absence of viable tumor cells on routine hematoxylin and eosin staining of resected tumors and lymph nodes; rate of major pathological responses defined as 10% or less viable tumor cells on routine hematoxylin and eosin staining of resected tumors)
- R0 resection rate
- Disease-free survival rate at 12 months per RECIST 1.1
- Overall survival rate at 12 months
- Safety and tolerability of preoperative immunotherapy
- Morbidity and mortality within 90 days of curative surgery

The primary endpoint was continuously monitored by the study statistician. At maximum 4 of 30 patients may experience a delay of curatively intended surgery beyond day 43 (with study treatment being administered on day 1), either due to toxicities or disease progression, to declare the study arm feasible. Continuous monitoring of prespecified stopping boundaries was applied to facilitate early termination of non-feasible study arms to reduce patient risks.

All secondary parameters were evaluated in an explorative or descriptive manner. Radiographic and nuclear imaging assessments at base line were conducted within standard of care at the study sites. Specifically, all 60 patients underwent whole body imaging by FDG-PET/CT. For exclusion of brain metastases, 41 patients underwent contrast-enhanced brain MRI scanning, 18 patients

underwent contrast-enhanced brain CT scanning (due to contraindications or intolerance of MRI imaging, or unavailability of an MRI slot within the protocol-defined screening period). In one patient with stage I B NSCLC no brain imaging was performed per Dutch guidelines. All patients underwent CT or PET/CT imaging immediately prior to surgery. Radiographic response was evaluated at the study sites following RECIST version 1.1. For exploratory analyses, nuclear imaging data were acquired prior to surgery. Histology and biomarker studies were conducted within standard of care at the study sites. PD-L1 expression by tumor cells was assessed locally using the primary antibody clone 22C3 (DAKO/Agilent M3653) following validated protocols with continuous external quality assurance (QUIP, UK NEQAS, NordiQC).

Exploratory endpoints are assessed in tumor and lymph node samples, blood cells, plasma and serum.

Plants

Seed stocks

Not applicable.

Novel plant genotypes

Not applicable.

Authentication

Not applicable.

Flow Cytometry

Plots

Confirm that:

- ☒ The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
- ☒ The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
- ☒ All plots are contour plots with outliers or pseudocolor plots.
- ☒ A numerical value for number of cells or percentage (with statistics) is provided.

Methodology

Sample preparation

Peripheral blood immune cells:

cryo-preserved peripheral blood mononuclear cells were thawed and rested overnight in RPMI medium supplemented with 10% fetal calf serum (FCS), 100 U/ml penicillin and 100 µg/ml streptomycin (PAA Laboratories) at 37°C in a 5% CO₂ atmosphere. Antibody staining of cell surface molecules (30min, 4°C) was followed by fixation and permeabilization for staining of intracellular markers (30 min, 4 °C).

Single cell suspensions from resected tumors:

Tumor tissue was put in 1 ml of digestion medium (DMEM/F12/HEPES solution supplemented with penicillin/streptomycin and 1% bovine serum albumin and containing collagenase, hyaluronidase and DNase I) and cut into small pieces. In order to facilitate dissociation the tissue was incubated for 40 minutes at 37 °C and pipetted every 10 minutes during the incubation period. The resulting cell suspension was transferred to a 50 ml centrifuge tube and centrifuged at 300×g for 10 minutes at ambient temperature. The pellet was resuspended in trypsin/EDTA and incubated for 5 minutes at ambient temperature. After inactivation of the trypsin by DMEM/F12/HEPES solution containing 10% FCS, the cell suspension was again triturated and filtered through a 40 µm cell strainer. After washing the filter with 50 ml PBS the cells were centrifuged at 400×g for 5 minutes at ambient temperature. Following one more washing step with phosphate-buffered saline, cell number and viability was measured using the NucleoCounter NC-3000 and one to two million cells per vial were cryopreserved in FCS-containing 10% DMSO.

Instrument

Peripheral blood immune cells:

Gallios flow cytometer (Beckman Coulter, Krefeld, Germany)

Single cell suspensions from resected tumors:

CytoFLEX LX (Beckman Coulter, Krefeld, Germany)

Software

Peripheral blood immune cells:

Kaluz software (Beckman Coulter), CytExpert V2.3 software (Beckman)

Single cell suspensions from resected tumors:

CytExpert V2.3 (Beckman Coulter, Krefeld, Germany) and FlowJo Software V10 (Tree Star, Ashland, USA)

Cell population abundance

Peripheral blood immune cells:

Samples containing 200,000 cells were stained with antibody panels for surface and intracellular markers. The minimum

abundance of CD8+ T cell subsets presented in the report was above 300 cells.

Single cell suspensions from resected tumors:

Two aliquots, each containing 500,000 cells, were stained with one of the two antibody panels for surface markers. The abundance of the specific cell populations presented in the report ranged from 6 to several hundred cells. Of note, in one patient no neutrophil granulocytes were identified in the sample.

Gating strategy

The gating strategies are graphically represented in Supplementary Figure 2.

☒ Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.